Anti-androgens for treatment of metastatic castration-sensitive prostate cancer

JP2024161428AInactive Publication Date: 2024-11-19ARAGON PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024129798
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-17
Filing Date
2024-08-06
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Benefits of technology

【0102】 製剤、組成物、又は成分に関して、本明細書で使用するとき、用語「許容可能な」とは 、治療中のヒト男性の全身的な健康に対する、その製剤、組成物又は成分の、その有害な 影響を実質的に上回る有益な効果を意味する。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161428000033
    Figure 2024161428000033
  • Figure 2024161428000034
    Figure 2024161428000034
  • Figure 2024161428000035
    Figure 2024161428000035
Patent Text Reader

Abstract

To provide a method for treating metastatic castration-sensitive prostate cancer in a male human.SOLUTION: The present invention provides a method comprising administering a therapeutically effective amount of an anti-androgen to a male human with metastatic castration-sensitive prostate cancer, where the anti-androgen is, for example, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N- methylbenzamide.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] (CROSS-REFERENCE TO RELATED APPLICATIONS) This application is a continuation of U.S. Provisional Patent Application No. 62 / 901,694, filed September 17, 2019. No. 62 / 836,920 filed April 22, 2019; No. 62 / 836,920 filed April 1, 2019 U.S. Provisional Patent Application No. 62 / 833,371, filed on March 2, 2019, and issued on March 22, 2019. U.S. Provisional Patent Application No. 62 / 822,312, filed February 8, 2019; No. 62 / 803,096, and U.S. Provisional Patent Application No. 6, filed January 30, 2019. 2 / 798,836, all of which claim the benefit of Family No. 60 / 699,999, filed on Dec. 1, 2003, which is incorporated herein by reference.

[0002] FIELD OF THE INVENTION Disclosed herein are methods for treating metastatic castration-sensitive prostate cancer with antiandrogens. As an antiandrogen, 4-[7-(6-cyano-5-trifluoromethylpyrrolidone] (3-in-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa -5-yl]-2-fluoro-N-methylbenzamide do not have. [Background technology]

[0003] Prostate cancer is the second most commonly diagnosed cancer and the sixth leading cause of cancer death in men. 14% (903,500) of all new cancer cases and 6% of all cancer deaths in men worldwide The progression from diagnosis to death of prostate cancer depends on the severity of the disease, hormone levels, and Mon status and presence or absence of detectable metastases: localized disease, detectable after radiation therapy or surgery Elevated prostate-specific antigen (PSA) levels without metastasis and non-castration stage or is best classified as a series of clinical stages based on clinical progression in the castration stage. Surgery, radiation, or a combination of these can be curative for patients with localized disease. However, a significant proportion of these patients will undergo relapse as evidenced by rising PSA levels. This can also lead to the formation of metastases, especially in high-risk groups, and progression to terminal disease. This may result in: Summary of the Invention [Problem to be solved by the invention]

[0004] Based on current guidelines, androgen deprivation therapy (ANDR) with or without docetaxel Hormone deprivation therapy (ADT) is a treatment for men with metastatic hormone-sensitive prostate cancer. It is considered to be an appropriate active control therapy. However, There is a clear and unmet medical need for alternative treatment options in mCSPC. There is a need for treatments that can slow the progression of the disease and associated morbidity. This would be of great clinical benefit in this patient population. The disclosed methods are useful for treating these and other important Regarding essential necessity. [Means for solving the problem]

[0005] Described herein are methods for treating metastatic castration-sensitive prostate cancer in human males. The method comprises administering a therapeutically effective amount of an antiandrogen to a subject having metastatic castration-sensitive prostate cancer. The invention relates to a method for producing a human subject, the method comprising, consisting of, or resulting from administering to a human male subject. In these methods, the antiandrogen is 4-[7-(6 -cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo- 5,7-Diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenz Amide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-di Methyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methyl Chilbenzamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]- 8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2- Fluoro-N-methylbenzamide, or N-{(2S)-1-[3-(3-chloro-4 -cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-(1- hydroxyethyl)-1H-pyrazole-3-carboxamide. In some embodiments, administration of an antiandrogen is to treat a patient with metastatic castration-sensitive prostate cancer. provides an increase in overall survival in human males compared to the overall survival rate of a human male comparison population, In another embodiment, the patient is administered a placebo in combination with androgen deprivation therapy. This comparison population is untreated. In a further embodiment, administration of an antiandrogen is Progression-free survival in human men compared with a comparison population of human men with castration-sensitive prostate cancer This comparison group provided increased progression survival and demonstrated placebo in combination with androgen deprivation therapy. In other embodiments, the comparison population is untreated.

[0006] In some embodiments, the male human is receiving treatment for cancer prior to administration of the antiandrogen. have received at least one prior therapy for the treatment of cancer The treatment is radiation therapy, surgical intervention, or docetaxel therapy. So, the human male has no prior experience with treatment.

[0007] In some embodiments, the antiandrogen is 4-[7-(6-cyano-5-trimethylsilyl]-2-(2-methyl-2-propanol)-4-[ ... (fluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro [3.4]oct-5-yl]-2-fluoro-N-methylbenzamide. In embodiments, antiandrogens generally, and more specifically 4-[7-(6-cyano-5 -trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazo Zaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide In still further embodiments, antiandrogens in general, and more particularly Specifically, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8- Oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro In some embodiments, oro-N-methylbenzamide is orally administered to a male human. , generally antiandrogens, more specifically 4-[7-(6-cyano-5-trifluoromethyl-2-methyl-2-oxo ... (3-methylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3 .4]oct-5-yl]-2-fluoro-N-methylbenzamide was administered continuously daily. In a further embodiment, the anti-androgen receptor antagonist is orally administered to a male human on a steroid-lowering schedule. hydrazines, more specifically 4-[7-(6-cyano-5-trifluoromethylpyridine- 3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5- yl]-2-fluoro-N-methylbenzamide is administered at a dose of approximately 30 mg per day. In a still further embodiment, the dosage is generally administered orally to a male human. Antiandrogens, more specifically 4-[7-(6-cyano-5-trifluoromethylpiperidin Lysin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octyl ter-5-yl]-2-fluoro-N-methylbenzamide is approximately 180 mg per day It is administered orally to a male human at a dose of about 480 mg per day. Antiandrogens in general, and more specifically 4-[7-(6-cyano-5-trifluoromethyl (ethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4 ]oct-5-yl]-2-fluoro-N-methylbenzamide is (a) administered in an amount of about 30 mg, (b) about 60 mg per day, (c) about 90 mg per day, (d) about or (d) at a dose of about 120 mg per day, or (e) at a dose of about 240 mg per day, administered orally to a human male. In some embodiments, antiandrogens generally, and more specifically 4-[7-( 6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo -5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzene Zucamide is administered orally to male humans at a dose of approximately 240 mg per day. In embodiments, antiandrogens in general, and 4-[7-(6-cyano-5-methyl-2-methyl-2-propanol]-2-one specifically, are used. (trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazas The dose of pyro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is If grade 3 or higher toxicity occurs in male humans, the dose should be increased to 180 mg / day or 1 mg / day. Reduced to 20 mg.

[0008] In certain embodiments, antiandrogens in general, and 4-[7-(6-cyano -5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7- Diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide (a) drugs that are potent inhibitors of CYP2C8 or CYP3A4; (b) drugs that are potent inhibitors of CYP3 A4, drugs metabolized primarily by CYP2C19 or CYP2C9, (c) UD P-glucuronosyltransferase (UDP-glucuronosyl transferase, UGT) or (d) P-glycoprotein (P-gp), a breast cancer resistance protein. Protein (breast cancer resistance protein, BCRP) or organic anion transporter Organic anion transporting polypeptide 1B1 (OATP1B1) Not co-administered with drugs that are substrates.

[0009] In some embodiments, antiandrogens generally, and more specifically, 4-[7-(6 -cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo- 5,7-Diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenz In a further embodiment, the amide is administered in combination with androgen deprivation therapy. antiandrogens, more specifically 4-[7-(6-cyano-5-trifluoromethyl (pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4] [Oct-5-yl]-2-fluoro-N-methylbenzamide is Gonadotropin-releasing hormone (GnRH) agonists or is administered in combination with an antagonist. GnRH agonists or antagonists include leuprolide, buserelin, and nafererin. , histrelin, goserelin, deslorelin, degarelix, ozarelix, ABT-6 20 (elagolix), TAK-385 (relugolix), EP-100, KLH-21 09, or triptorelin. In certain embodiments, generally is an antiandrogen, more specifically 4-[7-(6-cyano-5-trifluoromethyl Pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]o [Cth-5-yl]-2-fluoro-N-methylbenzamide in combination with bilateral orchiectomy It is used in conjunction with

[0010] In some embodiments, the antiandrogen is 4-(3-(4-cyano-3-(tri- (Fluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazol In a further embodiment, the compound is N-methylbenzamide. , 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl -4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzyl Nsamide is administered orally to male humans at a dose of approximately 160 mg per day.

[0011] In some embodiments, the antiandrogen is 4-[7-[4-cyano-3-(tri- fluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3. 4]oct-5-yl]-2-fluoro-N-methylbenzamide.

[0012] In some embodiments, the antiandrogen is N-{(2S)-1-[3-(3-chloro-N-methyl ... (4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5 -(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (darolutamide) In a further embodiment, N-{(2S)-1-[3-(3-chloro-4-cyano phenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxy Diethyl-1H-pyrazole-3-carboxamide is administered at a dose of 600 mg twice daily. In a further embodiment, N-{(2S)-1-[3-( 3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl }-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide is used in food It is administered orally to human males at a dose of 600 mg twice daily.

[0013] Further provided herein are methods for treating metastatic castration-sensitive prostate cancer in human males. A therapeutically effective amount of an antiandrogen is administered to a human male having metastatic castration-sensitive prostate cancer. and the method comprises administering to a subject a therapeutically effective amount of an antiandrogen. , 4-[7-(6-cyano-5-trifluoromethylpyridine trifluoromethylpyridine (3-in-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa -5-yl]-2-fluoro-N-methylbenzamide, 4-(3-(4-cyano-3- (Trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimide 4-[7-[4-(2-chloro-1-benzoxazolidin-1-yl)-2-fluoro-N-methylbenzamide Ano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-di Azaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide, is N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole -1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole The method is disclosed, wherein the compound is one or more of a hydroxybenzoate, ...

[0014] Further provided herein is a method of treating metastatic castration-sensitive prostate cancer in a human male. (a) determining whether a human male has metastatic castration-sensitive prostate cancer; b) administering an antiandrogen to a human in a therapeutically effective amount to treat metastatic castration-sensitive prostate cancer; and administering to the male, wherein the antiandrogen is 4-[7-(6-cyano-5-methyl-2-methyl-2-propanol]-2-one. (trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazas Pyrro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide, 4-(3 -(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo So-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide , 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6- Thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl Chilbenzamide, or N-{(2S)-1-[3-(3-chloro-4-cyanophenyl )-1H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl )-1H-pyrazole-3-carboxamide is disclosed.

[0015] Further provided herein is a method for treating metastatic castration-sensitive prostate cancer, comprising administering apalutamide The approved formulation containing α-tocopherol was administered to human men with metastatic castration-sensitive prostate cancer after the administration of the formulation. In some embodiments, the method comprises administering the compound of formula (I) to a subject in need thereof in an amount as described in the accompanying document. The approved product containing apalutamide is an ANDA product, a supplemental labeling application product, or a 505 (b)(2) Formulation. In some embodiments, the method comprises administering to a subject a clinically safe and / or effective formulation. It has been proven to be effective.

[0016] Further, the present specification defines a drug as being clinically proven to be safe and clinically effective. 1. A pharmaceutical product comprising apalutamide in an amount certified by the manufacturer, wherein the pharmaceutical product is packaged in a packaging and the packaging (a) identifies apalutamide as a regulatory approved chemical ingredient; and (b) the package insert directing the use of apalutamide in the treatment of castration-sensitive prostate cancer. Disclosed is a pharmaceutical product comprising:

[0017] Further provided herein is a method of marketing an approved formulation comprising apalutamide, the method comprising: includes marketing such preparations, and the formulation of a reference list drug for such preparations. The method is disclosed, wherein the package insert includes instructions for treating castration-sensitive prostate cancer. The specification further provides a method of offering for sale an approved formulation containing apalutamide, comprising: the method includes making an offer for sale of such a formulation; the reference drug product package insert includes instructions for treating castration-sensitive prostate cancer; In some embodiments, the formulation is an ANDA formulation, a supplemental indication application formulation, or is a 505(b)(2) formulation. [Brief explanation of the drawings]

[0018] The Summary of the Invention, as well as the Detailed Description below, should be read in conjunction with the accompanying drawings. For the purpose of illustrating the disclosed method, the drawings include exemplary embodiments of the method. However, the method is not limited to the specific embodiments disclosed herein. The drawings are as follows: [Figure 1] Outline of the phase III clinical trial design for apalutamide. ADT = androgen deprivation therapy. [Figure 2A] 1 is a graph showing Kaplan-Meier estimates of progression-free survival by radiological imaging. [Figure 2B] Forest plot of radiological progression-free survival by baseline patient characteristics. Analysis was performed using the log-rank test with stratification by Gleason score at diagnosis (≦7 vs. >7), region (North America and European Union vs. all other countries), and prior treatment with docetaxel (yes vs. no). [Figure 3A] Graph showing Kaplan-Meier estimates of overall survival. [Figure 3B] Forest plot of overall survival by baseline patient characteristics. Analysis was performed using the log-rank test, stratifying by Gleason score at diagnosis (≦7 vs. >7), region (North America and the European Union vs. all other countries), and prior treatment with docetaxel (yes vs. no). [Figure 4]Kaplan-Meier estimates of time to cytotoxic chemotherapy were performed using the log-rank test, stratifying by Gleason score at diagnosis (≤7 vs. >7), region (North America and European Union vs. all other countries), and prior treatment with docetaxel (yes vs. no). [Figure 5] Kaplan-Meier estimates of time to PSA progression are shown in the graph. Time to PSA progression was the time from the date of randomization to the date of PSA progression based on the Prostate Cancer Working Group 2 criteria. Analysis was performed using the log-rank test, stratifying by Gleason score at diagnosis (≤7 vs. >7), region (North America and the European Union vs. all other countries), and prior treatment with docetaxel (yes vs. no). [Figure 6] This graph shows Kaplan-Meier estimates of time to second progression-free survival. Second progression-free survival was the time from the date of randomization to the first occurrence of investigator-assessed disease progression (PSA progression, imaging progression, or clinical progression) while the patient was receiving first subsequent therapy for prostate cancer, or death from any cause, whichever occurred first. Analyses were performed using the log-rank test, stratifying by Gleason score at diagnosis (≤7 vs. >7), region (North America and the European Union vs. all other countries), and prior treatment with docetaxel (yes vs. no). [Figure 7] Figure 1 shows a graph of a repeated measures mixed-effects analysis of the mean change from baseline in the FACT-P total score. Error bars represent standard error. Raw FACT-P scores range from 0 to 156, with higher scores indicating better health-related quality of life. A 6- to 10-point change in the FACT-P total score is considered the minimally important difference. However, this figure shows the mean change in total score compared to baseline, not the raw total score. FACT-P, Functional Assessment of Cancer Therapy-Prostate. DETAILED DESCRIPTION OF THE INVENTION

[0019] Certain aspects of the invention are described herein for clarity in the context of separate embodiments. It will be appreciated that certain features may also be provided in combination in a single embodiment. That is, each individual embodiment is included unless expressly incompatible or specifically excluded. are considered combinable with any other embodiment, and such combinations are not considered to be part of another embodiment. Conversely, for ease of explanation, the embodiments may be considered in the context of a single embodiment. The different features of the invention described may be provided separately or in any subcombination. Finally, the embodiments may be implemented as part of a series of steps or as part of a larger structure. Although each step may be considered an independent embodiment in itself, , and can be combined with others.

[0020] The transitional phrases "comprising" and "consisting essentially of" "ly of" and "consisting of" are generally accepted terms in patent language. is intended to imply the meanings set forth therein, namely, (i) "comprises" or "contains" "featuring" is synonymous with "including," "containing," or "featuring" and is inclusive or non-exclusive. It is intended to be limiting and not to exclude other unrecited elements or method steps. and (ii) "consisting of" is not specified in the claims. and (iii) "consisting essentially of" The patent application is based on the identified material or process and the basic and novel feature(s) of the claimed patent. ) and more specifically, limit the scope of the claims to those that do not substantially affect the fundamental and A novel feature is that the method compares the viability of a human male comparison population, as described elsewhere herein. The present invention provides a method for improving the survival of human male populations compared to the conventional method, including, but not limited to, improving the survival of human male populations compared to the conventional method. It is related to being able to provide at least one of the benefits described in the specification.

[0021] Embodiments described with the term "comprising" (or its equivalents) may also In embodiments, the terms "consisting of" and "consisting essentially of" are independently described. Provide what can be used.

[0022] When values ​​are expressed as approximations, by use of the descriptor "about," the particular value shall remain the same. It is understood that the use of the term "about" generally refers to the general purpose of the disclosed invention. It indicates approximations that may vary depending on the desired properties sought to be obtained by the subject matter, and its function The term "common sense" should be interpreted in the context of the specific context in which it is used. This can be interpreted as a matter of routine. The number of significant figures provided may be one non-limiting way of determining the extent of the term "about." In other cases, the incremental changes used in a series of values ​​may be used to refer to each value using the term "about If present, all ranges are inclusive. is generic and combinable, i.e., references to values ​​stated in ranges Includes all values ​​of

[0023] Unless otherwise specified, the term "about" means a ±10% variation of the associated value, but In some embodiments, the variation is ±5%, ±15%, ±20%, ±25%, or ±50%. This also includes cases where:

[0024] Certain features of the invention are described herein for clarity in the context of separate embodiments. It will be appreciated that certain features may also be provided in combination in a single embodiment. That is, unless expressly incompatible or specifically excluded, each individual embodiment , are considered combinable with any other embodiment, and such combinations are not considered to be part of another embodiment. Conversely, for simplicity of explanation, the invention may be described in the context of a single embodiment. The different features of the invention described may be provided separately or in any subcombination. Finally, the embodiments may be implemented as part of a series of steps or as part of a larger structure. Although the steps may be described as separate steps, each step may be considered an independent embodiment in itself and may be used independently of the others. Combinations are possible.

[0025] Where a list is presented, unless otherwise specified, each individual element of the list and its sublists It should be understood that all combinations of the above are separate embodiments. A list of embodiments presented as "A," "B," "C," or "D" is not intended to be limiting. shall be construed to include "A or B," "A or C," "B or C," or "A, B, or C." It is.

[0026] The present invention should be read in conjunction with the accompanying figures and examples, all of which form a part of this disclosure. The present invention can be more readily understood by reference to the following description. It is not intended to be limited to the specific products, methods, conditions or parameters described or shown in the specification. The terminology used herein is for the purpose of describing specific embodiments by way of example only. are for illustrative purposes only and are not intended to limit any claimed invention. Likewise, unless otherwise specified, possible mechanisms or modes of action or modifications Any statements regarding the reasons are intended to be merely exemplary and the invention herein is not intended to be limiting. the accuracy or inaccuracy of any such proposed mechanism or mode of action or reason for improvement; Throughout this document, these statements are used in various It is recognized that the present invention refers to compounds, compositions, and methods of using those compounds and compositions. That is, in this disclosure, features or embodiments relating to the composition or methods of using the composition are When describing or claiming embodiments, such descriptions or claims may include those features or embodiments. The embodiments are to be extended to each of these contexts (i.e., compositions and methods of use). It is understood that the present invention is intended to

[0027] The androgen receptor (AR) is a steroid and nuclear receptor Within this large family of proteins, the vertebrate spindle There are only five known steroid receptors: androgen receptors, estrogen receptors, and These include the progesterone receptor, the glucocorticoid receptor, and the mineralocorticoid receptor. AR is a soluble protein that acts as an intracellular transcription factor. It is regulated by androgen binding, which leads to receptor-protein interaction. Sequential conformational changes in the receptor occur that affect its function and receptor-DNA interaction. Cut.

[0028] The AR is involved in androgen target tissues such as the prostate, skeletal muscle, liver, and central nervous system (CNS). NS), with the highest expression levels in the prostate, adrenal gland, and epididymis. endogenous androgen, such as testosterone and 5-dihydrotestosterone (5a-DHT) It can be activated by binding of an agonist.

[0029] The androgen receptor (AR) is a 110 kD nuclear receptor located in Xql 1-12. When activated by androgens, it mediates the transcription of target genes and stimulates the prostate epithelium. Regulates cell growth and differentiation. Like other steroid receptors, the unbound form of the AR is primarily It is located in the cytoplasm and binds to heat shock proteins through interaction with the ligand-binding domain. Upon agonist binding, the AR undergoes a series of conformations. This causes the heat shock proteins to dissociate from the AR, and the transformed AR dimerizes and It undergoes phosphorylation and nuclear localization mediated by a nuclear localization signal. The receptors used consisted of a six-nucleotide half-site complex with three random nucleotides between them. androgen response element (ARE) characterized by the census sequence 5'-TGTTCT-3' It binds to and is located in the promoter or enhancer region of the target of the AR gene. By recruiting transcriptional coregulators (including coactivators and corepressors) and the transcription machinery These processes further ensure the transactivation of AR-regulated gene expression. All of these processes are initiated by ligand-induced conformational changes in the ligand-binding domain. It will begin.

[0030] In genetic males with loss-of-function AR mutations and in mice genetically engineered to lack AR, AR signaling is essential for the prostate gland to function properly, as evidenced by the lack of glandular development or prostate cancer progression. This is important for the development and maintenance of male reproductive organs, such as the prostate gland. Dependence continues during neoplastic transformation. Androgen deprivation (e.g., GnRH antagonist) androgens) remain the mainstay of prostate cancer treatment. Removal of the hormone is usually effective for a limited period of time, and prostate cancer develops and develops into circulating androgen. Even low levels of rhodamine restore growth potential.

[0031] Castration-resistant prostate cancer (CRPC) is a terminal condition CRPC is a rare phenotype, and almost all patients die from prostate cancer. While a small proportion of these patients bypass the need for AR signaling, most of the patients with CRPC Most cases are classified as "androgen-independent prostate cancer" or "hormone-refractory prostate cancer." Although termed AR-associated phenotypes, they retain their lineage dependence on AR signaling.

[0032] Prostate cancer is the second most common cause of cancer death in men in the United States, killing 6 in 10 men in the United States. Approximately 1 in 10 people will be diagnosed with the disease during their lifetime. Targeted treatment fails in 30% of men, who develop recurrent disease. The disease usually first manifests as elevated plasma prostate-specific antigen (PSA), followed by distant metastases. Prostate cancer cells have the ability to regulate androgen receptors (ARs) for growth and survival. ), these men are more likely to take drugs that block testosterone production. (e.g., GnRH agonists) alone or in combination with any residual testosterone AR Treatment is usually with antiandrogens (e.g., bicalutamide) to antagonize the effects of androgen depletion. This approach has resulted in a decline in PSA and visible tumor regression (if present) in some patients. However, after this, castration-resistant prostate cancer (CRP) C) and most patients ultimately die. Study shows CRPS continues to depend on AR signaling, key to acquired resistance The mechanism has been demonstrated to be increased levels of AR protein (Nat.Med, 2004,10,33-39). Activity in castration-sensitive and castration-resistant prostate cancer AR-targeting agents with potent anti-cancer drugs hold promise for the treatment of this terminal disease.

[0033] The progression from diagnosis to death in prostate cancer varies depending on the extent of disease, hormonal status, and detectable metastases. Presence or absence of metastasis, localized disease, no detectable metastasis after radiation therapy or surgery, prostate-specific antigen Based on elevated PSA levels and clinical metastasis in the non-castrated or castrated stage. It is best classified as a series of clinical stages. Surgery, radiation, or a combination of these may be used to treat localized It can be curative for patients with sexual disorders, but a significant proportion of these patients have recurrent disease as evidenced by rising PSA levels, which is also particularly This may result in the formation of metastases in the tumor group and progression to the terminal stage of the disease.

[0034] Androgen ablation is the standard of care and generally results in good outcomes, i.e., PSA decline, tumor size, and A plateau in which no proliferation occurs, followed by recurrence as castration-resistant disease, can be predicted. Molecular profiling studies of advanced prostate cancer generally focus on the androgen receptor (AR) gene. Increased AR expression is indicated, which may occur through gene amplification or other mechanisms.

[0035] Antiandrogens are useful in treating early-stage prostate cancer. In many cases, the disease progresses in the presence of continued androgen deprivation or antiandrogen therapy. Cases of antiandrogen withdrawal syndrome also progress to a "hormone refractory" stage. Antiandrogen withdrawal syndrome has been reported after long-term treatment with antiandrogens. Clinically observed tumor regression or symptomatic relief observed upon cessation of antiandrogen therapy These anti-AR mutants are defined from the perspective of the receptor binding specificity. The agonistic ability of androgens may at least partially account for this phenomenon. For example, hydroxyflutamide and bicalutamide are T877A and W7 It acts as an AR agonist in the 41L / W741C AR mutant.

[0036] Bicalutamide inhibits the growth of prostate cancer cells in conditions where AR overexpression has led to castration resistance. Certain antiandrogen compounds, such as benzodiazepines, have mixed antagonist / agonist properties. It has been demonstrated that (Science, 2009 May 8;324(5928):7 87-90) This agonistic activity may result in a clinical finding known as antiandrogen withdrawal syndrome. This antiandrogen withdrawal syndrome is useful for explaining the effects of AR antagonists. Approximately 30% of men receiving rituximab experienced a decline in serum PSA when treatment was discontinued. (J Clin. Oncol, 1993.11(8):p.1566-72).

[0037] Prostate Cancer Stages In the early stages of prostate cancer, the cancer is confined to the prostate gland. In these early stages, treatment Typically involves either surgical removal of the prostate or radiation therapy to the prostate. In some patients, prostate cancer is localized and no active treatment is performed. In the early stages where intervention is required, surgery or radiation therapy can destroy cancer cells. In approximately 30% of cases, these procedures fail and the prostate Adenocarcinoma continues to progress, typically as evidenced by rising PSA levels. Men whose prostate cancer progresses after these early treatment regimens have progressive or recurrent prostate cancer. It is said that...

[0038] Prostate cancer cells depend on the androgen receptor (AR) for growth and survival. Men with advanced prostate cancer are taking drugs that block testosterone production (e.g., GnR H agonist) alone or in combination with any residual testosterone to determine the effect of AR These are treated with antiandrogens (e.g., bicalutamide) that antagonize the effects of androgens. Treatment of steroids reduces serum testosterone to castrate levels, which generally lasts for some time. This approach has been shown to result in PSA decline and delayed disease progression in some patients. However, ultimately, This is followed by a recurrence called castration-resistant prostate cancer (CRPC), and most patients eventually Castration-resistant prostate cancer (CRPC) occurs when prostate cancer spreads to other parts of the body. Cancer is classified as non-metastatic or metastatic depending on whether it has spread to other parts of the body.

[0039] Estimates from European country-specific registries suggest that approximately 15%–30% of men diagnosed with prostate cancer % of patients had metastatic (M1) castration-sensitive prostate cancer For example, Flamand V , et al., Prog Urol. 2008;18:53-59. In the United States, patients presenting with mCSPC account for approximately 4% of all prostate cancer diagnoses. K, et al. Urology 2010;75:1396-1405. This difference This may result from differences in the use of PSA screening in different regions. chroder FH,et al.,Eur Urol.2012;62:745-7 52 However, in 2012, the United States Preventive Services Task Force The USPSTF issued a recommendation against PSA screening. Since PSA screening seems to have decreased since then, The proportion of men in the United States who experience this condition may be increasing. Drazer MW, et al. ,J Clin.Oncol 2015;33:2416 2423, Lin K,et al.Agency for Healthcare Research and Q uality,2011;No.12-05160-EF-1.

[0040] Prostate cancer cells depend on AR signaling for their growth and survival. The standard treatment for patients with mCSPC is androgen deprivation therapy (ADT). Androgen deprivation therapy is a form of medical castration (i.e., gonadotropin-releasing hormone analogs). gonadotropin [GnRHa; agonist or antagonist]) or surgical castration (i.e., bilateral To prevent tumor flare in subjects with clear metastases, Use a short course of first-generation antiandrogens and then start a GnRH agonist It can reduce the testosterone flare associated with

[0041] antiandrogens As used herein, the term "antiandrogen" refers to a generally accepted It interferes with the biological effects of androgens on normally responsive tissues in the body. It may refer to a group of hormone receptor antagonist compounds that can inhibit In some embodiments, the antiandrogen is a small molecule. In some embodiments, the antiandrogen is an AR antagonist. In some embodiments, the antiandrogen is an AR full antagonist. The androgen is a first generation antiandrogen. In some embodiments, the antiandrogen Antiandrogens are second-generation antiandrogens.

[0042] As used herein, the terms "AR antagonist" or "AR inhibitor" refer to and inhibit, i.e., decrease, at least one activity of an AR polypeptide. Exemplary AR activities include coactivator binding, DNA binding, These include, but are not limited to, ligand binding or nuclear translocation.

[0043] As used herein, a "full antagonist" refers to a compound that, at effective concentrations, inhibits the activity of an AR polypeptide. As used herein, an antagonist refers to an antagonist that essentially completely inhibits the activity of a peptide. A "partial antagonist" is capable of partially inhibiting the activity of an AR polypeptide, but not of inhibiting its activity at all. Refers to an antagonist that is not a complete antagonist even at high concentrations. " refers to a polypeptide that exhibits at least about 80%, at least about 90%, or at least about 100% of the activity of an AR polypeptide. at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least means about 99% or greater inhibition.

[0044] As used herein, the term "first-generation antiandrogen" refers to an antiandrogen that inhibits the activity of wild-type AR. It refers to drugs that exhibit antagonist activity against polypeptides. It has been reported that progenitors can act as agonists in castration-resistant prostate cancer (CRPC). First-generation antiandrogens differ from second-generation antiandrogens in that they Exemplary first-generation antiandrogens include flutamide, nilutamide, and bicalcamide. These include, but are not limited to, mido.

[0045] As used herein, the term "second-generation antiandrogen" refers to an agent that inhibits the activity of wild-type AR. This refers to drugs that exhibit complete antagonist activity against polypeptides. Procarcinogens are used in cells with increased expression levels of AR (e.g., castration-resistant prostate cancer (CRC)). It is similar to first-generation anti-inflammatory drugs in that it acts as a complete antagonist in Exemplary second-generation antiandrogens include 4-[7-(6 -cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo- 5,7-Diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenz Amide (also known as apalutamide, ARN-509, or JNJ-56021927, CAS No. No. 956104-40-8), 4-(3-(4-cyano-3-(trifluoromethyl) fluoride) (phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)- 2-Fluoro-N-methylbenzamide (also known as MDV3100 or enzalutamide, CA S No. 915087-33-1), 4-[7-(4-cyano-3-trifluoromethyl (phenyl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5-yl 1-[(2-fluoro-N-methylbenzamide)(RD162, CAS no. 915087- 27-3), and N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1 H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1 H-pyrazole-3-carboxamide (also known as darolutamide). In embodiments, the second-generation antiandrogen binds to the ligand-binding portion of an AR polypeptide. The AR polypeptide binds to the AR polypeptide at or near the position.

[0046] [ka] 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-Thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide (apalutamide)

[0047] [ka] 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl -4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzyl Enzalutamide (enzalutamide)

[0048] [ka] 4-[7-(4-cyano-3-trifluoromethylphenyl)-8-oxo-6-thio 5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl Benzamide (RD162)

[0049] [ka]

[0050] N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole -1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole In some embodiments, the 3-carboxyamide (darolutamide) Antiandrogens contemplated in this method include those that inhibit AR nuclear translocation, such as darolutamide. Inhibits DNA binding to the agonist response element and coactivator recruitment. In some embodiments, the antiandrogens contemplated in the methods described herein are AR overactive. It does not exhibit agonist activity in expressing prostate cancer cells.

[0051] Apalutamide is a second-generation antiandrogen that binds directly to the ligand-binding domain of AR. It is a steroid drug that impairs nuclear translocation, AR binding to DNA, and AR target gene regulation, This inhibits tumor growth and promotes apoptosis. It binds to AR with higher affinity than non-castrated hormone-sensitive prostate cancer and bicalutamide-resistant Induces partial or complete tumor regression in a human prostate cancer xenograft model (Cle gg et al.Cancer Res.March 15,2012 72;149 4) Apalutamide suppresses the partial remission seen with bicalutamide in the setting of AR overexpression. Lacking anti-inflammatory activity.

[0052] Darolutamide, BAY1841788, or ODM-201, exists as two diastereomers. AR antagonists, including ORM-16497 and ORM-16555. The scientific name is N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyra 1-(2-hydroxypropyl)-5-(1-hydroxyethyl)-1H-pyrazol-1-yl It is a benzodiazepine-3-carboxamide, which has a similar effect to other second-generation antiandrogens. Darolutamide has activity against known AR mutants that are resistant to AR. androgen-induced nuclear translocation of AR and transcription of AR gene targets. Matsubara, N., Mukai, H., Hosono, A. et al .Cancer Chemother Pharmacol(2017)80:1063 .

[0053] Specific Terms For the avoidance of doubt, terms used herein have their generally accepted meanings. To aid in understanding, some definitions are provided here.

[0054] As used herein, the term "cancer" refers to a cancer that tends to grow uncontrolled and in some cases It refers to an abnormal proliferation of cells that tends to infiltrate (spread) in some cases.

[0055] As used herein, the term "prostate cancer" refers to histologically or cytologically confirmed prostate cancer. This refers to adenocarcinoma.

[0056] The term "androgen deprivation therapy (ADT)" refers to the treatment of androgen levels in patients with prostate cancer. This refers to the reduction of testosterone levels to castrate levels (<50 ng / dL). Treatment includes orchiectomy or administration of gonadotropin-releasing hormone agonists or antagonists. ADT includes surgical castration (removal of the testicles) and / or the use of steroids. or luteinizing hormone-releasing hormone (L Gonadotropin-releasing hormone (HRH) / GnRH agonists or antagonists Examples of GnRH agonists or antagonists include Leuconostoc and leuconostoc. Prolide, buserelin, naferelin, histrelin, goserelin, deslorelin, degas Relics, Ozarelix, ABT-620 (elagolix), TAK-385 (relagolix) EP-100, KLH-2109, or triptorelin, or In certain embodiments, examples of GnRH agonists include goserelin acetate, hydroxybenzoates, and hydroxybenzoates. These include strelin acetate, leuprolide acetate, and triptorelin palmate.

[0057] The term "localized advanced prostate cancer" refers to a condition in which all active cancer cells are present in the prostate and related or adjacent organs. It refers to prostate cancer that appears exclusively in the gallbladder (e.g., seminal vesicles, bladder neck, and rectal wall).

[0058] The term "high-risk localized prostate cancer" refers to patients with metastatic or recurrent disease after primary therapy with curative intent. In some embodiments, metastatic forms of prostate cancer are considered to be metastatic. High risk of maturation was <20 months, <19 months, <18 months, <17 months, and <16 months. , <15 months, <14 months, <13 months, <12 months, or <11 months, <10 months, < 9 months, <8 months, <7 months, <6 months, <5 months, <4 months, <3 months, <2 months, or is a prostate specific antigen doubling time (P) of <1 month. In some embodiments, a high risk for metastasis formation is defined as: Defined as a prostate-specific antigen doubling time (PSADT) of <10 months. In some cases, a high risk for metastasis formation is associated with a high Gleason score or large tumor size. It is defined as:

[0059] For the avoidance of doubt, the terms "castration-sensitive prostate cancer" and "hormone-sensitive prostate cancer" are used interchangeably. They have the same meaning and are used interchangeably.

[0060] The terms "castration-sensitive prostate cancer" and "hormone-sensitive prostate cancer" refer to localized disease, biochemical androgen deprivation therapy (ADT) either as a primary relapse or in the metastatic setting. This refers to cancer that responds to

[0061] The terms "metastatic castration-sensitive prostate cancer" and "metastatic hormone-sensitive prostate cancer" refer to the Invasion (metastasis) of the cancer to other areas, such as the bones, lymph nodes, or other parts of the body Refers to cancer that responds to androgen deprivation therapy (ADT).

[0062] The term "non-metastatic castration-sensitive prostate cancer" refers to the treatment of men with non-invasive (metastatic) castration-sensitive prostate cancer. In some embodiments, non-metastatic cancers are those that respond to antidepressant therapy (ADT). Prostate cancer is sensitive to bone scans and computed tomography (CT). evaluated by magnetic resonance imaging (MRI) scans. As used herein, the term "CRPC" refers to castration-resistant prostate cancer. CRPC refers to the progression of prostate cancer despite the suppression of male hormones that stimulate the growth of prostate cancer cells. , a prostate cancer that continues to grow.

[0063] The term "metastatic castration-resistant prostate cancer" refers to castration-resistant prostate cancer that has spread to other parts of the body. Refers to...

[0064] Metastatic castration-sensitive prostate cancer (CSPC) remains responsive to testosterone suppression therapy This refers to prostate cancer.

[0065] As used herein, the term "NM-CRPC" refers to non-metastatic castration-resistant prostate cancer. In some embodiments, NM-CRPC is diagnosed by bone scan and computed tomography. It is evaluated by computed tomography (CT) or magnetic resonance imaging (MRI) scan.

[0066] The term "chemotherapy-naive metastatic castration-resistant prostate cancer" refers to cancer that has not previously been treated with chemotherapy. This refers to metastatic castration-resistant prostate cancer that has not been treated with chemotherapy.

[0067] The term "metastatic castration-resistant prostate cancer after abiraterone acetate-prednisone treatment" refers to the Refers to metastatic castration-resistant prostate cancer that has been previously treated with abiraterone.

[0068] The term "high-risk NM-CRPC" refers to the progression of metastatic disease in men with NM-CRPC. In some embodiments, a high risk for metastasis formation is <20 months, <19 months, <18 months, <17 months, <16 months, <15 months, <14 months, < 13 months, <12 months, or <11 months, <10 months, <9 months, <8 months, <7 months, Prostate-specific antigen fold increase of <6 months, <5 months, <4 months, <3 months, <2 months, or <1 month In some embodiments, the high activity associated with metastasis formation is defined as the post-surgery dose-dependent agonist activation time (PSADT). Risk is defined as a prostate-specific antigen doubling time (PSADT) of <10 months. In some embodiments, the high risk of metastasis formation is a locoregional recurrence (e.g., a tumor in the primary tumor bed, bladder neck, anastomosis, and pelvic lymph nodes).

[0069] As used herein, the term "co-administration" or the like refers to the administration of selected therapeutic agents to a single patient. and the drugs are administered by the same or different routes of administration, or by the same or different routes of administration. It is intended to include a therapeutic regimen that is administered over time.

[0070] As used herein, the term "pharmaceutical combination" refers to a mixture of two or more active ingredients. or products resulting from combinations, including fixed and non-fixed combinations of active ingredients. The term "fixed combination" includes both combinations of the active ingredients, e.g. Both palutamide and the co-agent may be administered to the patient simultaneously in a single unit or dosage form. The term "non-fixed combination" means a combination of active ingredients, e.g., apalutamide and The co-medications may be administered either simultaneously, concurrently, or sequentially, without any specific interruption time limit. The compounds are administered to a patient as separate units or separate dosage forms, and such administration results in a This means providing safe and effective levels of the two active ingredients in It also applies to cocktail therapy, eg the administration of three or more active ingredients.

[0071] The term "FDHT-PET" refers to 18F-16P-fluoro-5a-dihydrotestosterone. This refers to positron emission tomography (PET), which uses a tracer based on dihydrotestosterone. This technology allows for visual assessment of ligand binding to the androgen receptor in patients. This can be used to evaluate the pharmacokinetics of androgen receptor-directed therapy. .

[0072] The term "continuous daily dosing schedule" does not include drug holidays for a particular therapeutic agent. In some embodiments, continuous daily administration of a particular therapeutic agent. A dosing schedule involves administering a particular therapeutic agent at approximately the same time each day.

[0073] The terms "treat" and "treatment" refer to the treatment of a patient affected by a condition, including killing cancer cells. It not only alleviates the pathological condition by increasing the level of the hormone, but also inhibits the progression of the disease. and includes slowing the rate of progression, stopping the rate of progression, ameliorating the condition, and curing the condition. Unless otherwise specified, the term "treat" also includes treatment as a therapeutic measure (i.e., prophylaxis). " and "treatment" refer to the totality of the effects described, however, in other embodiments, these terms may also refer to any one of the effects described, or at least one of It can also refer to something that excludes effects.

[0074] The term "metastasis-free survival" or "MFS" refers to the time it takes for cancer to spread over a defined period or to death. MFS refers to the proportion of subjects in a clinical trial who survive without any adverse events. MFS is reported as the time from enrollment, randomization, or start of treatment in an individual. In the setting of treatment of CRPC with antiandrogens, Therefore, the increase in metastasis-free survival was associated with increased risk of invasive disease, whichever occurs first, compared with placebo treatment. In some embodiments, the patient is observed without cancer or death. The increase in metastasis-free survival was approximately 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, Approximately 7 months, approximately 8 months, approximately 10 months, approximately 11 months, approximately 12 months, approximately 13 months, approximately 14 months, Approximately 15 months, approximately 16 months, approximately 17 months, approximately 18 months, approximately 19 months, approximately 20 months, or approximately 20 In some embodiments, the administration of a safe and effective amount of an antiandrogen is Also provided is increased metastasis-free survival in human males, optionally wherein the increased metastasis-free survival is non-metastatic castration-resistant. Relative to the mean survival rate of a population of placebo-treated human men with active prostate cancer In some embodiments, metastasis-free survival is determined by BICR, whichever occurs first. First report of distant metastases of bone or soft tissue or death from any cause confirmed by This refers to the period from randomization to time of evidence.

[0075] The term "time to metastasis" refers to the BICR of radiographically detectable bone or soft tissue distant metastases. The time from randomization to the time of the first scan showing evidence confirmed by MRI. In some embodiments, administration of a safe and effective amount of an antiandrogen is continued for a period of time until metastasis. Improves antitumor activity as measured by time to metastasis (TTM).

[0076] The term "radiographic progression-free survival" refers to the time to progressive disease, whichever occurs first. Time from randomization to first imaging documentation of disease or death. worsening of soft tissue lesions as measured by computed tomography or magnetic resonance imaging, or If a subject has either a new lesion on bone scan or a new lesion on radiological imaging, the subject will be Patients are considered to have progressive disease.

[0077] The term "progression-free survival" is based on RECIST v1.1 and is defined as follows: Defined as: For subjects with at least one measurable lesion, progressive disease is considered curable. Defined as an increase of at least 20% in the sum of target lesion diameters, based on the smallest sum in the study (This includes the baseline total, if smallest in the trial). 20% relative increase In addition to the increase, the sum must also show an absolute increase of at least 5 mm. The appearance of new lesions on CT or MRI scans is also considered progression. For subjects with only nonmeasurable disease, overt progression (change in overall disease status) Progression was considered to occur when there was a significant decrease in the disease (representing a progressive disease) or the appearance of one or more new lesions. For new bone lesions detected, a second imaging modality (e.g., CT or In some embodiments, a safe and effective amount of an antiandrogen Administration of improves anti-tumor activity as measured by progression-free survival.

[0078] The term "prostate cancer-specific survival" refers to the time from randomization to the date of death due to prostate cancer. is defined as:

[0079] The term "PFS2" refers to the time from randomization in the first trial to the onset of a second disease progression or progression of any cause. This refers to the time to death due to

[0080] The term "time to disease progression" refers to either of the following (whichever occurs first): ), defined as the time from randomization to CRF documentation: (1) skeletal-related events Skeletal-related event (SRE) development: pathologic fracture, spinal cord compression, or surgical intervention (2) the need for intervention or radiation therapy; (3) the need for disease-related intervention requiring the initiation of new systemic anticancer therapy; (3) progression or worsening of associated pain; or (4) localized disease requiring surgical intervention or radiation therapy. The development of clinically significant symptoms due to regional tumor progression. and administration of an effective amount of an antiandrogen improves antitumor activity as measured by disease progression. do.

[0081] The term "time to pain progression" refers to the time to pain progression (two consecutive assessments separated by at least 3 weeks). Brief Pain Inventory-Short Form (BPI-SF) mean increase of 2 points from baseline in worst pain intensity, whichever comes first Whatever may occur, there is no reduction in opioids or initiation of chronic opioids in patients with a ≥4 Pain exacerbation is defined as the time from randomization to the worst pain score (with the mean worst pain score). For the duration endpoint, the BPI-SF worst pain score (item 3) is used. The scale ranges from 0 to 10, with lower scores representing lower levels of pain intensity and 2 being The changes were minimally important differences.

[0082] The term "time to skeletal-related event (SRE)" refers to the time to an SRE (symptomatic pathological fracture, spinal cord compression, etc.). Date of randomization to the date of first observed event (anxiety, radiation to bone, or surgery to bone) It is defined as the period from

[0083] The term "time to chronic opioid use" refers to the time from the date of randomization to the date of confirmed chronic opioid use. Chronic opioid use is defined as the time to first day of opioid use. Administration of opioid analgesics for more than 3 weeks for oral preparations and more than 7 days for parenteral preparations Patients already receiving opioids at study entry were considered to have chronic Sexual opioid use should be continued for ≥3 weeks for oral preparations or ≥7 days for parenteral preparations. defined as a ≥ 30% increase in the total daily dose of opioid analgesics following an opioid overdose. administration of opioid analgesics as needed for treatments other than prostate cancer (e.g., non-immobilized In the case of chronic opioid use (continuous or unscheduled administration), No stop was necessary.

[0084] The term "time to symptomatic local progression" refers to the time to symptomatic local progression, whichever occurs first. Symptomatic local progression is defined as the time from the date of randomization to progression. Examples of symptomatic local progression include: These include, but are not limited to, urethral obstruction or bladder outlet obstruction.

[0085] The term "time to worsening of ECOG PS grade" refers to the time to worsening of ECOG PS grade. defined as the time from the date of randomization to the first date of a worsening of (defined as a worsening of the patient's ECOG PS grade at baseline).

[0086] The term "overall survival" is defined as the time from randomization to the date of death from any cause. Survival data for subjects alive at the time of analysis are defined as those whose survival is known. In addition, subjects who were not alive after the baseline information were excluded from the study. Data for participants were censored on the date of randomization, and those who could not be tracked due to unknown whereabouts were included. For subjects who become unresponsive or withdraw consent, data will be retained until the subject's survival is known. In some embodiments, the study was discontinued at the most recent date for which safety and efficacy were confirmed. Administration of effective doses of antiandrogens improves antitumor activity as measured by overall survival .

[0087] The term "time to cytotoxic chemotherapy" refers to the time until the documentation of a new cytotoxic chemotherapy. Defined as the period from randomization.

[0088] The term "progression-free survival with first subsequent therapy (PFS2)" refers to the progression-free survival (PFS) of Investigator-assessed disease progression (PSA, X-ray, or other biomarkers) during the first subsequent anticancer therapy radiographic, symptomatic, or any combination) or the initiation of a second subsequent anticancer therapy The time to death (any cause) before the start of treatment is defined as the time from randomization to death.

[0089] The term "time to PSA progression" is based on the Prostate Cancer Working Group 2 criteria. Defined as the time from randomization to the date of SA exacerbation. Scher HI, et al. J Clin Oncol 2008;26:1148-1159.

[0090] The term "time to second progression-free survival" refers to the time until a patient reaches prostate cancer, whichever occurs first. Investigator-assessed disease progression (PSA progression) while receiving first-line subsequent cancer therapy Time to first occurrence of refractory disease (e.g., radiographic progression, or clinical progression) or death from any cause , defined as the time from randomization.

[0091] For subjects without documented progression after subsequent therapy, progression data are progression-free. In some embodiments, safety and mortality are censored at the most recent date known to be fatal or at the date of death. Administration of an effective amount of an antiandrogen is associated with improved progression-free survival as measured by first subsequent therapy. In addition, it improves antitumor activity.

[0092] According to the Prostate Cancer Working Group (PCWG2) criteria Therefore, prostate-specific antigen response and time to PSA progression were assessed at the time of the primary MFS analysis. The time to PSA progression is evaluated when the PCWG2 criteria for PSA progression are met. The time to treatment is calculated as the time from randomization to the time point.

[0093] As used herein, the term "placebo" does not include second-generation antiandrogens. In the context of the treatment of metastatic castration-sensitive prostate cancer, the administration of a pharmaceutical composition Men receiving progesterone or placebo were compared with those receiving GnRH agonists / antagonists. Castrate levels of testosterone are continuously maintained by either topical administration or orchiectomy. It is necessary to

[0094] As used herein, the term "survival effect" refers to the effect of a randomized controlled trial of an administered drug on a patient's survival. In some embodiments, survival refers to an increase in a patient from the time of induction to death. The effect lasts for about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 15 months, about 20 months, about 25 months, about 30 months, about 35 months, approximately 40 months, approximately 45 months, approximately 50 months, approximately 55 months, approximately 60 months, approximately 80 months , about 100 months, or more than 100 months.

[0095] As used herein, the term "delay in symptoms associated with disease progression" refers to the delay in symptoms associated with the administration of a drug. Increased time from randomization to the onset of symptoms such as pain or urinary obstruction in clinical trials of the drug and increased time for quality of life considerations.

[0096] The term "randomization," when referring to a clinical trial, refers to the time at which patients are identified as eligible for the clinical trial. This refers to the time when a patient is assigned to a treatment group.

[0097] The terms "kit" and "article of manufacture" are used synonymously.

[0098] The terms "subject" and "patient" and "human" are used interchangeably.

[0099] Routes of Administration and Pharmaceutical Compositions The therapeutic agents described herein may be administered in any suitable manner or in any suitable formulation. Suitable routes of administration of drugs include oral and parenteral (e.g., intravenous, subcutaneous, intramuscular). All formulations are in dosages suitable for administration to humans. The Pharmaceutical Compositions Summary is incorporated herein by reference for such disclosure, e.g. , Remington: The Science and Practice of P. harmacy,Nineteenth Ed(Easton,Pa.:Mack Pu blishing Company,1995);Hoover, John E., Re mington's Pharmaceutical Sciences,Mack P publishing Co.,Easton,Pennsylvania 1975;L iberman, H.A. and Lachman, L., Eds., Pharmace. utical Dosage Forms,Marcel Decker,New Yo rk,NY,1980; and Pharmaceutical Dosage For ms and Drug Delivery Systems,Seventh Ed. (Lippincott Williams & Wilkins 1999) There are.

[0100] Safety studies also identify any potential adverse effects that exposure to a drug may have. Effectiveness is often determined by appropriate circumstances, e.g., tightly controlled Active pharmaceutical ingredients have been shown to have greater health benefits than placebo or other interventions when tested in controlled clinical trials The variance is measured by determining whether the variance exhibits

[0101] Unless otherwise indicated, as used herein, the terms "effective amount" or "therapeutically effective amount" mean or to treat an underlying disease or condition, including halting or slowing the progression of the disease or condition. The dose of antiandrogen used in this study is the dose of antiandrogen used in this study.

[0102] As used herein, the term "acceptable" with respect to a formulation, composition, or ingredient means , the harmful effects of the formulation, composition or ingredients thereof on the general health of the human male under treatment. This means that the beneficial effects substantially outweigh the adverse effects.

[0103] In some embodiments, the antiandrogen is present in a solid oral dosage form. In embodiments, the antiandrogen is in an oral dosage form, a unit oral dosage form, or a solid dosage form. In some embodiments, the compound is formulated as a pharmaceutical composition (e.g., a capsule, tablet, or pill). For example, the antiandrogen is formulated as a tablet. The drug is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl) -8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2 In some embodiments, the antiandrogen is -fluoro-N-methylbenzamide. The agent is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl (4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methyl In some embodiments, the antiandrogen is 4-[7-[4 -cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7 -diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide In some embodiments, the antiandrogen is N-{(2S)-1-[3-( 3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl }-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide. The formulation may also contain a combination of two or more of these materials. Solid oral dosage forms containing the steroid agent are disclosed in International Publication No. WO 2005 / 024990, each of which is incorporated herein by reference. As disclosed in Chinese Patent No. 2014113260 and Chinese Patent No. 104857157, or may be provided as a capsule, each of which is incorporated herein by reference. International Publication Nos. 2016090098, 2016090101, and 2016090 105 and 2014043208. Suitable techniques for preparing the solid oral dosage forms of the present invention are described in detail in Remington's Pharmaceuticals, Inc. Ceutical Sciences,18th edition,edited by AR. Gennaro, 1990, Chapter 89 and Remington-T he Science,and Practice of Pharmacy,21st edition, 2005, Chapter 45.

[0104] In certain embodiments, the antiandrogen is provided in a solid unit dosage form and in a solid form suitable for oral administration. The unit dosage form may be approximately 10, 20, 30, 40, 50, or 60 mg of the active ingredient per unit dosage form. , 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160 , 170, 180, 190, 200, 210, 220 or 240 mg, or any of these The antiandrogen may be present in an amount within the range of values ​​bracketed.

[0105] To prepare the pharmaceutical compositions of the present invention, the active pharmaceutical ingredient is mixed with the pharmaceutical composition by conventional pharmaceutical compounding techniques. The pharmaceutical composition is thoroughly mixed with a pharmaceutical carrier, which carrier is then mixed in the desired preparation for administration (e.g., oral or parenteral). Depending on the form of the formulation, it can take a wide variety of forms. Suitable pharmaceutically acceptable carriers include: A description of some of these pharmaceutically acceptable carriers is well known in the art. , published by the American Pharmaceutical Association and the British Pharmaceutical Association. Pharmaceutical Excipients.

[0106] For example, dry powders for reconstitution or inhalation, granules, capsules, caplets, gelcaps, Solid oral dosage forms such as pills and tablets (each including immediate-release, sustained-release, and extended-release formulations) In the formulation, suitable carriers and additives include diluents, granulating agents, lubricants, binders, glidants, Disintegrants and the like are included, but are not limited to these. Capsules are the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated with sugar, gelatin, or other suitable coatings by standard techniques. The formulation may be coated, film coated, or enteric coated.

[0107] Preferably, these compositions are administered orally, intranasally, sublingually, intraocularly, transdermally, parenterally, intravaginally, Tablets, pills, capsules, etc. for administration by dry powder inhalation or other inhalation or delivery means. capsules, dry powders for reconstitution or inhalation, granules, lozenges, sterile solutions or suspensions, metered dose It is a unit dosage form such as an aerosol or liquid spray, drops, or suppository.

[0108] These formulations are manufactured by conventional formulation techniques. To prepare the formulation, the main active ingredient is mixed with a pharmaceutical carrier, such as a diluent, binder, adhesive, disintegrant, The tablet is mixed with conventional tablet-forming ingredients such as lubricants, anti-adherents, and glidants. Starches (i.e., those that can be hydrolyzed, such as corn starch, wheat starch, etc.) starch, or potato starch), lactose (granulated, spray-dried, or anhydrous), sucrose sucrose, sucrose-based diluents (confectionery manufacturer's sugar; sucrose + about 7-10% by weight of invert sugar; Sucrose + about 3% by weight of modified dextrin; sucrose + about 4% by weight of invert sugar, about 0. 1-0.2% by weight of corn starch and magnesium stearate), dextromethorphan cellulose, inositol, mannitol, sorbitol, microcrystalline cellulose (i.e., FM AVICEL microcrystalline cellulose available from C Corp.), dicalcium phosphate, Examples include, but are not limited to, calcium sulfate dihydrate, and calcium lactate trihydrate. Suitable binders and adhesives include acacia gum, guar gum, and tragacanth gum. , sucrose, gelatin, glucose, starch, and cellulosic (i.e., Methylcellulose, sodium carboxymethylcellulose, ethylcellulose, hydro hydroxypropylmethylcellulose, and hydroxypropylcellulose), water-soluble or Dispersible binders (i.e., alginic acid and its salts, magnesium aluminum silicate, hydroxybenzoates, Hydroxyethylcellulose [i.e., available from Hoechst Celanesel] [Polyesteryl ester], polyethylene glycol, polysaccharide acid, bentonite, polyvinylpyrrolidone lolidone, polymethacrylate, and pregelatinized starch), but these Suitable disintegrants include, but are not limited to, starch (corn, potato, etc.), Sodium Starch Glycolate, Pregelatinized Starch, Clay (Magnesium Aluminum Silicate) Nesium), Cellulose (Cross-linked Sodium Carboxymethylcellulose and Microcrystalline cellulose), alginates, pregelatinized starches (i.e., corn starch, etc.), Gums (i.e., agar, guar, carob, karaya, pectin, and tragacanth gum) , as well as cross-linked polyvinylpyrrolidone and the like. Suitable lubricants and anti-blocking agents include stearates (magnesium, calcium, and Sodium), stearic acid, talc wax, stearowet, boric acid Acid, Sodium Chloride, DL-Leucine, Carbowax 4000, Carbowax 600 0, sodium oleate, sodium benzoate, sodium acetate, sodium lauryl sulfate Examples of suitable anti-inflammatory agents include, but are not limited to, magnesium sulfate, magnesium lauryl sulfate, and the like. Suitable lubricants include talc, corn starch, and silica (i.e., C available from Cabot). AB-O-SIL Silica, SYLO available from W.R. Grace / Davison ID silica, and AEROSIL silica available from Degussa). Sweeteners and flavoring agents may be used to improve the palatability of the oral dosage form, including, but not limited to: Additionally, colorants and coatings may be added to the drug solid dosage form. They may be added or applied to solid dosage forms for ease of identification or for aesthetic purposes. The carrier is formulated with a pharmaceutical active agent to deliver a precise and appropriate dose of the pharmaceutical active agent to the patient. provides targeted release characteristics.

[0109] One aspect of the present invention is a solid dispersion comprising an antiandrogen. There are various techniques for this, including melt extrusion (e.g., hot melt extrusion), Spray drying and solution evaporation are included, especially hot melt extrusion and spray drying, with spray drying being preferred. One aspect of the present invention is a particle comprising a solid dispersion as described herein. In one aspect, particles as described herein are available, particularly suitable In a suitable solvent, antiandrogens in general, and more specifically, ARN-509 and H It can be obtained by spray drying a mixture containing PMCAS. The materials are available, particularly by melt extrusion.

[0110] HPMCAS, or Hydroxypropyl Methylcellulose Acetate Succinate Hypromellose acetate succinate (CAS number 71138-97-1) is a It is a mixture of acetate and monosuccinate esters of hydroxypropyl methylcellulose. (IUPAC name: Cellulose, 2-hydroxypropyl methyl ether, acetate, hydrogen butanedioate). Degree of substitution / substitution rate (acetyl content, succinic acid content) and particle size (micronized Various grades are available, differentiated based on their size (wt. and granularity). The HPMCAS in the dispersion with ARN-509 was HPMCAS LG (Granular Gray). HPMCAS LF (micronized grade) (Shin-Etsu Chemical l Co., Ltd.), and in particular HPMCAS LG.

[0111] Suitable binders for use in the pharmaceutical compositions provided herein include starch, cellulose, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carbohydrates, Carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose cellulose, hydroxypropyl methylcellulose), polyvinyl 1-pyrrolidone, and Examples include, but are not limited to, mixtures of these.

[0112] Examples of suitable fillers for use in the pharmaceutical compositions provided herein include microcrystalline cellulose, cellulose, powdered cellulose, mannitol, lactose, calcium phosphate, starch , pregelatinized starch, and mixtures thereof.

[0113] A binder or filler in pharmaceutical compositions typically accounts for about 50 to 100% of the total mass of the pharmaceutical composition or dosage form. It is present at about 99% by weight.

[0114] Disintegrants are used in the composition to provide tablets that disintegrate when exposed to an aqueous environment. Tablets containing too much disintegrant may disintegrate during storage. On the other hand, tablets containing too little may disintegrate at a desired rate or under desired conditions. Therefore, it is important that the amount is not excessively large enough to adversely alter the release of the active ingredient. A sufficient amount of disintegrant, but not too little, must be used to form a solid oral dosage form. The amount of disintegrant used varies based upon the type of formulation, and is readily discernible to those of ordinary skill in the art. Typical pharmaceutical compositions contain from about 0.5 to about 15% by weight of a disintegrant, particularly from about 1 to about Disintegrants that can be used in the pharmaceutical compositions provided herein include 5% by weight of a disintegrant. The drugs used include croscarmellose sodium, crospovidone, and sodium starch glycolate. Thorium, potato starch or tapioca starch, pregelatinized starch, other starches These include, but are not limited to, polyethylene, other celluloses, gums, and mixtures thereof. .

[0115] Lubricants that can be used in the pharmaceutical compositions provided herein include stearin Calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol , polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, Sodium stearyl fumarate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil) oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), stearate lead, ethyl oleate, ethyl laurate, agar, and mixtures thereof. Lubricants are typically used in pharmaceutical compositions or formulations in which they are incorporated. It is used in an amount of less than about 1% by weight of the formulation.

[0116] The compressed tablet formulation may optionally be filled with a filler to provide color, light protection, and / or taste masking. Tablets may also be film-coated to minimize the patient's biological exposure to the API. The onset and / or rate of release in the gastrointestinal tract may be adjusted to optimize or maximize It may be coated.

[0117] Hard capsule formulations are made of, for example, gelatin or hypromellose shells with an aqueous soluble sorbent. Manufactured by filling a blend or granulation of lutamide or enzalutamide can be done.

[0118] A softgel capsule formulation can be prepared.

[0119] Pharmaceutical compositions intended for oral use include solid dispersion formulations and the like, which can be prepared by the methods described herein. The blended materials may be prepared by other methods known in the art for preparing pharmaceutical compositions. Such compositions may be sweetened to provide a pharmaceutically excellent and palatable preparation. Further containing one or more agents selected from the group consisting of taste agents, flavoring agents, coloring agents, and preservatives. You may do so.

[0120] Tablets are prepared by mixing the active ingredient with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, granulating agents, and disintegrating agents. Disintegrants, binders, glidants, lubricants, and antioxidants, such as propyl gallate, butylated hydroxybenzoates, The tablets may be uncoated. It may be coated or film coated to modify the appearance. or to prolong the action by delaying disintegration and absorption in the gastrointestinal tract , may be coated with a functional coat.

[0121] Compositions for oral use also include those in which the active ingredient is not present in an inert solid diluent, such as calcium carbonate. capsules (e.g., hard gelatin capsules) mixed with starch, calcium phosphate, or starch or when the active ingredient is in a liquid or semi-liquid form, e.g., peanut oil, liquid paraffin soft gelatin capsules mixed with glycerides, surfactants, or olive oil Aqueous suspensions may be prepared by dissolving the active substances in excipients suitable for the manufacture of aqueous suspensions. It contains in a mixed state a dispersible substance suitable for preparation of an aqueous suspension by adding water. Powders and granules are mixed with a dispersing or wetting agent, a suspending agent, and one or more preservatives. In certain embodiments of the present invention, the pharmaceutical compositions of the present invention are obtained by dissolving the active ingredient in a diluent system. , disintegrant, salt, lubricant, glidant, and film coating, each in an amount of about 3% to about 5% by weight / weight. 8wt / wt%, about 4wt / wt% to about 20wt / wt%, about 4wt / wt% to about 20wt Amount / wt%, approx. 0.5 wt / wt% to approx. 4 wt / wt%, approx. 0 wt / wt% to approx. 2 wt / % wt., and about 1% wt. / wt. to about 5% wt. / wt., or about 18% wt. / wt., respectively. ~40 wt / wt%, approx. 7 wt / wt%~approx. 15 wt / wt%, approx. 7 wt / wt%~approx. 18 wt / wt%, approx. 1.0 wt / wt% ~ approx. 3.0 wt / wt%, approx. 0.1 wt / wt % to about 1.0 wt / wt%, and at concentrations of about 2.0 wt / wt% to about 4.0 wt / wt% In certain embodiments, the solid dispersion formulation comprises a diluent, one or more disintegrants, a lubricant, and An exemplary blended composition or oral dosage form is blended with mannitol, fine particles, and a lubricant. Microcrystalline cellulose, croscarmellose sodium, sodium chloride, colloidal silica, Contains sodium stearyl fumarate, and magnesium stearate.

[0122] The disintegrant is about 4% w / w to about 20% w / w, or about 7% w / w to about 15% w / w. A salt may also be present, such as sodium chloride. , potassium chloride, or a combination thereof. , present in a concentration of about 5% w / w to about 35% w / w of the final pharmaceutical composition.

[0123] In certain embodiments, the inactive ingredients of the core tablet include anhydrous colloidal silica, croscarmellose, Sodium cellulose, hydroxypropyl methylcellulose acetate succinate, Magnesium tearate, microcrystalline cellulose, and silicified microcrystalline cellulose. In embodiments, the tablets contain the following excipients: black iron oxide, yellow iron oxide, polyethylene A film coating consisting of polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. It is finished with coating.

[0124] In another embodiment, a single unit dose of the pharmaceutical composition contains about 60 mg of apalutamide. In some embodiments, the pharmaceutical composition comprises a single A single unit-administered multiple dose comprises, consists of, or consists of about 60 mg of apalutamide. It consists essentially of, for example, four or individual unit dosage forms, which are administered to a human. The total daily dose of apalutamide may be about 240 mg per day.

[0125] In some embodiments, a single unit dose of the pharmaceutical composition comprises about 40 mg of enzalutamide. In some embodiments, the pharmaceutical composition comprises, consists of, or consists essentially of A single unit dose of the composition contains approximately 40 mg of enzalutamide, or consisting essentially of, for example, four or individual unit dosage forms The total daily dose of enzalutamide may be about 160 mg per day.

[0126] In still further embodiments, a single unit dose of the pharmaceutical composition contains about 300 mg of darolutamide. In some embodiments, the pharmaceutical composition comprises, consists of, or consists essentially of A single unit dose of the composition contains approximately 300 mg of darolutamide, or consisting essentially of, for example, two or individual unit dosage forms The total daily dose of darolutamide may be approximately 600 mg twice daily. The total daily dose of darolutamide may be about 1200 mg per day.

[0127] All formulations for oral administration are in a form suitable for such administration.

[0128] Administration Methods and Treatment Regimen In one embodiment, there is provided a method of treating metastatic castration-sensitive prostate cancer in a human male, comprising: administering a therapeutically effective amount of an antiandrogen to a human male with metastatic castration-sensitive prostate cancer comprising, consisting of, or consisting essentially of administering an anti-inflammatory drug The androgenic agent is 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl )-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- 2-Fluoro-N-methylbenzamide, 4-(3-(4-cyano-3-(trifluoro Methyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidine-1 -yl)-2-fluoro-N-methylbenzamide, 4-[7-[4-cyano-3-(trimethylsilyl)-2-fluoro-N-methylbenzamide (trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3 .4]oct-5-yl]-2-fluoro-N-methylbenzamide, or N-{(2S )-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propanol propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide In the following disclosure, the method is described herein, wherein the compound is at least one of the following: In this regard, the "method of treating metastatic castration-sensitive prostate cancer" is a "method of treating metastatic castration-sensitive prostate cancer" For brevity, each possible Possible alternatives are not analyzed, but each is considered separately as if fully described. will be done.

[0129] Described herein are methods for treating metastatic castration-sensitive prostate cancer in human males. Therefore, a therapeutically effective amount of an antiandrogen is administered to a human male with metastatic castration-sensitive prostate cancer. and administering to a subject in need thereof a method for treating a subject in need thereof, the method comprising ... -[7-(6-cyano-5-trifluoromethylpyridine]trifluoromethylpyridine -3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5 -yl]-2-fluoro-N-methylbenzamide, 4-(3-(4-cyano-3-(trimethylsilyl)-2-fluoro-N-methylbenzamide, (trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazo Lysin-1-yl)-2-fluoro-N-methylbenzamide, 4-[7-[4-cyano -3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diaza spiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide, or N -{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole-1 -yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3 -carboxamides.

[0130] In another aspect described herein, the administration of an antiandrogen is in the setting of metastatic castration-sensitive pre-cancerous metastasis. Provides increased overall survival in human men compared to the overall survival rate of a comparison population of human men with prostate cancer The comparison group received a placebo in combination with androgen deprivation therapy, and the placebo In other embodiments, the comparison is performed before or during administration of the antiandrogen. The population is treatment-naive. In other aspects described herein, the administration of the antiandrogen comprises: Compared with the overall survival of a comparison population of men with metastatic castration-sensitive prostate cancer, It provides an increase in overall survival, and the comparison population is administered androgen deprivation therapy. In one embodiment, administration of an antiandrogen is to a human male with metastatic castration-sensitive prostate cancer. providing an increase in overall survival in human males compared to the overall survival rate of a gender comparison population, the comparison population comprising: In certain embodiments, administration of an antiandrogen is Overall survival in human men with castration-sensitive prostate cancer compared with the overall survival in a comparison population of human men and the comparison group provided an increase in the number of men with androgen deprivation therapy. In some embodiments, a first generation antiandrogen is administered. Both the drug-treated population and the comparison population were treated with the same or similar prior treatment regimen. have been previously treated.

[0131] In a further embodiment, administration of an antiandrogen is to treat a patient with metastatic castration-sensitive prostate cancer. provides increased progression-free survival in human males compared to the progression-free survival rate in a human male comparison population, The comparison group receives a placebo in combination with androgen deprivation therapy. In other described embodiments, administration of an antiandrogen is to treat a patient with metastatic castration-sensitive prostate cancer. providing increased progression-free survival in human males compared to the progression-free survival rate in a comparison population of human males; The comparison population has previously been administered androgen deprivation therapy. Androgen administration prevents progression in a comparison population of men with metastatic castration-sensitive prostate cancer. and providing increased progression-free survival in human males compared to survival in a comparison population previously treated with In certain embodiments, administration of an antiandrogen is Progression-free survival in human men with prostate cancer compared with the progression-free survival rate in a comparison population of human men and the comparison group provided an increase in the number of men with androgen deprivation therapy. A first generation antiandrogen has been previously administered. Again, in a preferred embodiment, Both the prodrug-treated population and the comparison population received the same or similar prior treatment regimen. have been previously treated with

[0132] In one aspect, a method of treating metastatic castration-sensitive prostate cancer comprises administering to a subject a therapeutically effective amount of an anti-cancer drug. The method includes administering a prostatogenic agent to a human male with metastatic castration-sensitive prostate cancer. and the antiandrogen is administered orally. In some embodiments, the antiandrogen is In some embodiments, the antiandrogen is administered twice daily. In some embodiments, the antiandrogen is administered three times daily. In some embodiments, the antiandrogen is administered four times daily. In some embodiments, the antiandrogen is administered every other day. In some embodiments, the antiandrogen is administered twice a week. In some embodiments, the antiandrogen is administered every other week. In this form, the antiandrogen is administered orally on a continuous daily dosing schedule.

[0133] In one embodiment, the desired dose is administered in a single dose or simultaneously (or over a short period of time). In divided doses given or at appropriate intervals, for example, two, three, four or more times per day In some embodiments, the anti-androgen receptor antagonist may be administered in subdoses of 100 mg / kg or more. The agonist is preferably given once daily in divided doses administered simultaneously (or closely spaced apart). In some embodiments, the antiandrogen is administered twice daily in equal doses. In some embodiments, the antiandrogen The agent is conveniently given in divided doses administered three equally divided times daily. In this embodiment, the antiandrogen is given in divided doses administered four equally divided times daily. It is convenient to be able to do this.

[0134] In certain embodiments, the antiandrogen is delivered in fractional unit doses throughout the day. The desired doses are given in 1, 2, 3, or 4 increments throughout the day so that the total amount of steroids added up to the total daily dose. It may be delivered in 4, 5, 6, 7, 8, 9, or 10 subunit doses.

[0135] In a further embodiment, 4-[7-(6-cyano-5-trifluoromethylpyridine-3 -yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5-yl

[00100] 2-fluoro-N-methylbenzamide was administered daily to a male human. In some embodiments, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl )-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- 2-Fluoro-N-methylbenzamide is administered orally to male humans. In the form 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl) -8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2 -Fluoro-N-methylbenzamide was administered to male humans on a continuous daily dosing schedule. It is administered orally.

[0136] In a further embodiment, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl )-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-furan In yet a further embodiment, fluoro-N-methylbenzamide is administered daily to a male human. is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl (4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methyl The benzamide is orally administered to a male human. In some embodiments, the 4-(3-(4 -cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2 -thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide It is administered orally to male humans on a continuous daily dosing schedule.

[0137] In a further embodiment, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl ]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]- 2-Fluoro-N-methylbenzamide is administered daily to a male human. In the form 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-ox So-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro In some embodiments, 4-N-methylbenzamide is orally administered to a male human. -[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thio 5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl Benzamide is administered orally to male humans on a continuous daily dosing schedule.

[0138] In a further embodiment, N-{(2S)-1-[3-(3-chloro-4-cyanophenyl )-1H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl )-1H-pyrazole-3-carboxamide was administered daily to a male human. In some embodiments, N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1 H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1 H-pyrazole-3-carboxamide was orally administered to male humans. In the form N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyridinyl] {5-(1-hydroxyethyl)-1H-pyridazol-1-yl}propan-2-yl}-5-(1-hydroxyethyl)-1H-pyridazol-1-yl Benzalazole-3-carboxamide was administered orally to male humans on a continuous daily dosing schedule. It is given.

[0139] In some embodiments, the antiandrogen is a second generation antiandrogen. In certain embodiments, the antiandrogen is enzalutamide, apalutamide, RD-16 2, or darolutamide. In some embodiments, the antiandrogen is apalta In some embodiments, the antiandrogen is enzalutamide. In some embodiments, the antiandrogen is RD-162. In this case, the antiandrogen is darolutamide.

[0140] Generally, antiandrogens used to treat the diseases or conditions described herein in humans are Doses of steroids typically range from 10 mg to 1000 mg per day. In this embodiment, the antiandrogen is administered in a dose ranging from about 30 mg per day to about 1200 mg per day. In some embodiments, the antiandrogen is administered orally to a human at a dose of 1 g per day. It is administered orally to humans at doses of about 30 mg per day to about 600 mg per day. In embodiments, the antiandrogen is administered at a dose of about 30 mg per day, about 60 mg per day, Approximately 90 mg per day, approximately 120 mg per day, approximately 160 mg per day, approximately 180mg, approximately 240mg per day, approximately 300mg per day, approximately 390mg per day g, approximately 480 mg per day, approximately 600 mg per day, approximately 780 mg per day, It is administered orally to humans at a dose of about 960 mg per day, or about 1200 mg per day.

[0141] In certain embodiments, the compounds are used to treat the diseases or conditions described herein in humans. The doses of antiandrogens used are 30-40 mg / day, 40-50 mg / day, and 50-60 mg / day. mg / day, 60~70mg / day, 70~80mg / day, 80~90mg / day, 90~10 0mg / day, 100-120mg / day, 120-140mg / day, 140-160mg / day, 160~180mg / day, 180~200mg / day, 200~220mg / day, 22 0~240mg / day, 240~260mg / day, 260~280mg / day, 280~30 0mg / day, 300~320mg / day, 320~340mg / day, 340~360mg / day Days, 360-380mg / day, 380-400mg / day, 400-420mg / day, 42 0-440 mg / day, 440-460 mg / day, 460-480 mg / day, or Any range defined by two or more of these ranges, or any range recited within these ranges, The value may have any discrete value that is determined by the

[0142] In some embodiments, the compounds are used to treat a disease or condition described herein in a human. The dose of antiandrogens used is 0.3-0.4 mg / kg / day, 0.4-0.5 mg / kg / day, kg / day, 0.5-0.6 mg / kg / day, 0.6-0.7 mg / kg / day, 0.7-0 .8mg / kg / day, 0.8-0.9mg / kg / day, 0.9-1mg / kg / day, 1- 1.2 mg / kg / day, 1.2 to 1.4 mg / kg / day, 1.4 to 1.6 mg / kg / day , 1.6-1.8mg / kg / day, 1.8-2mg / kg / day, 2-2.2mg / kg / day, 2.2-2.4 mg / kg / day, 2.4-2.6 mg / kg / day, 2.6-2.8 mg g / kg / day, 2.8-3.0 mg / kg / day, 3.0-3.2 mg / kg / day, 3.2 ~3.4mg / kg / day, 3.4~3.6mg / kg / day, 3.6~3.8mg / kg / day, 3.8-4.0 mg / kg / day, 4.0-4.2 mg / kg / day, 4.2-4.4 mg g / kg / day, 4.4-4.6 mg / kg / day, 4.6-4.8 mg / kg / day, or Any range defined by two or more of these ranges, or within these ranges Any individual values ​​cited may be used.

[0143] In a further embodiment, 4-[7-(6-cyano-5-trifluoromethylpyridine-3 -yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5-yl [Isopropyl]-2-fluoro-N-methylbenzamide is administered at a dose of approximately 30 mg per day to approximately 100 mg per day. In a still further embodiment, 4-[7- (6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thiox So-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzyl In humans, benzodiazepines are administered at doses of approximately 180 mg to 480 mg per day. In certain embodiments, 4-[7-(6-cyano-5-trifluoromethyl] (pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4] Oct-5-yl]-2-fluoro-N-methylbenzamide (a) about 3 times a day 0 mg, (b) approximately 60 mg per day, (c) approximately 90 mg per day, (d) approximately 100 mg per day or (d) administered orally to a human male at a dose of about 120 mg per day, or (e) about 240 mg per day. In some embodiments, 4-[7-(6-cyano-5-trifluoromethylpyridine -3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5 -yl]-2-fluoro-N-methylbenzamide at a dose of approximately 240 mg per day It is administered orally to human males.

[0144] In some embodiments, 4-[7-(6-cyano-5-trifluoromethylpyridine -3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5 -yl]-2-fluoro-N-methylbenzamide doses in human males with grade 3 or higher If toxicity occurs, the dose may be reduced to 180 mg per day. The original dose may be maintained until symptoms improve to Grade 1 toxicity or less. The amount may be reduced as described herein or may be increased to the original dose with continued monitoring. In some embodiments, 4-[7-(6-cyano-5-trifluoromethyl-2-methyl-2-propanol]-2-one may be used. (fluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro [3.4]oct-5-yl]-2-fluoro-N-methylbenzamide dose in humans If a man experiences intolerable side effects, the dose is reduced to 180 mg per day. In embodiments, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)- 8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2- Doses of fluoro-N-methylbenzamide caused grade 3 or higher toxicity in male humans Alternatively or additionally, if toxicity symptoms are Grade 1 or The original dosage may be maintained until the toxicity improves to below the threshold, and then the dosage is increased to or resumed at the original dose with continued monitoring. In some embodiments, 4-[7-(6-cyano-5-trifluoromethylpiperidinyl] Lysin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octyl Doses of tert-5-yl]-2-fluoro-N-methylbenzamide were intolerable to human males. If side effects occur, the dose is reduced to 120 mg per day.

[0145] In some embodiments, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)- Nyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2 -Fluoro-N-methylbenzamide is administered orally at a dose of approximately 160 mg per day. In some embodiments, greater than 160 mg of enzalutamide is administered per day.

[0146] In some embodiments, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]phenyl] nyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl ]-2-fluoro-N-methylbenzamide is administered at a dose of approximately 30 mg per day to approximately 4 mg per day. In yet a further embodiment, 44-[7- [4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5 ,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzaldehyde Mido was orally administered to male humans at doses of approximately 180 mg per day to approximately 480 mg per day. In certain embodiments, 4-[7-[4-cyano-3-(trifluoromethyl) Phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5- (a) about 30 mg per day, (b) about 30 mg per day of [[[(2-fluoro-N-methylbenzamide)]]]-2-fluoro-N-methylbenzamide ) approximately 60 mg per day, (c) approximately 90 mg per day, (d) approximately 120 mg per day or (d) orally administered to a male human at a dose of about 240 mg per day. In an embodiment, 44-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8 -oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fu Fluoro-N-methylbenzamide was administered orally to male humans at a dose of approximately 240 mg per day. It is given.

[0147] In some embodiments, N-{(2S)-1-[3-(3-chloro-4-cyanophenoxy)methyl] 1H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazol-1-yl]propan-2-yl (ethyl)-1H-pyrazole-3-carboxamide at a dose of approximately 1200 mg per day In some embodiments, more than 1200 mg of N-{( 2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl ]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide Boxamide is administered.

[0148] In certain embodiments, where no improvement in the state of the disease or condition in humans is observed, anti-androgen In some embodiments, a once-daily dosing schedule is used. In some embodiments, the drug is administered twice daily. To increase the amount of antiandrogen, a three times daily dosing schedule is used.

[0149] In some embodiments, the amount of antiandrogen administered to a human is determined by the severity of the disease or condition. The condition and severity, as well as the identity of the person (e.g., weight), and the specific additional Varies depending on factors such as, but not limited to, therapeutic agents (if applicable) .

[0150] In some embodiments, the human male has received at least one prior therapy for the treatment of cancer. The patient received chemotherapy and the prior therapy for the treatment of cancer was radiation therapy, surgical intervention, or docetaxel. In some embodiments, the male human is treatment-naive.

[0151] In some embodiments, the antiandrogen is administered in combination with androgen deprivation therapy. In a further embodiment, the antiandrogen is administered in combination with at least one gonadotropin. It is administered in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist. In still further embodiments, the at least one GnRH agonist or antagonist is: Leuprolide, buserelin, nafererin, histrelin, goserelin, deslorelin, Degarelix, ozalelix, ABT-620 (elagolix), TAK-385 (relagolix), EP-100, KLH-2109, or triptorelin; or Including that.

[0152] A physician may prescribe a GnRH agonist according to instructions, recommendations, and practice. In some embodiments, the gonadotropin-releasing hormone agonist or antagonist is In some embodiments, leuprolide is administered at about 7.5 mg every 4 weeks. g, or 22.5 mg every 3 months, or about 30 mg every 4 months, or about every 6 months It is administered as a depot injection at a dose of 45 mg. It is administered over a period of about 3 days to about 12 months. 0.01 mg to about 200 mg of leuprolide, preferably for a period of about 3 days to about 12 months In some embodiments, the leuprolide is administered at a dose of about 3.6 mg of leuprolide. The gonadotropin-releasing hormone agonist or antagonist is buserelin. In some embodiments, the gonadotropin-releasing hormone agonist or antagonist is In some embodiments, the gonadotropin-releasing hormone agonist is nafererin. Or the antagonist is histrelin. In some embodiments, the gonadotropin A releasing hormone agonist or antagonist is histrelin acetate. In an embodiment, the histrelin acetate is administered at a dose of about 50 mg of histrelin over a 12 month period. Histrelin acetate or approximately 50 μg of histrelin acetate per day. In some embodiments, the GnRH agonist or antagonist is goserelin. In embodiments, goserelin is administered at a dose of about 3.6 mg every 4 weeks or about 10.8 mg every 12 weeks. In some embodiments, goserelin is administered as a subcutaneous implant in an amount of about 28 days. about 0.01 mg to about 20 mg of goserelin, preferably about 2 mg, for a period of about 3 months Goserelin is administered at a dose of approximately 3.6 mg to approximately 10.8 mg over a period of 8 days to approximately 3 months. In some embodiments, the GnRH agonist or antagonist is deslorelin. In some embodiments, a gonadotropin-releasing hormone agonist or antagonist In some embodiments, the degarelix is ​​about 240 mg It is administered as a subcutaneous injection at a dose of 100 mg, followed by approximately 80 mg every four weeks. In some embodiments, the GnRH agonist or antagonist is ozarelix. In some embodiments, the GnRH agonist or antagonist is ozarelix. In some embodiments, the GnRH agonist or antagonist is ABT-620 ( In some embodiments, the GnRH agonist or antagonist In some embodiments, the GnRH antagonist is TAK-385 (relugolix). In some embodiments, the GnRH inhibitor or antagonist is EP-100. The agonist or antagonist is KLH-2109. The gonadotropin-releasing hormone agonist or antagonist is triptorelin. In some embodiments, triptorelin is administered at a dose of about 0.01 mg for a period of about 1 month. ~ about 20 mg of triptorelin, preferably about 3.75 mg over a period of about 1 month It is administered with triptorelin.

[0153] In certain embodiments, antiandrogens are used in combination with bilateral orchiectomy. In certain embodiments, the antiandrogen is administered after bilateral orchiectomy.

[0154] In yet a further embodiment, 4-[7-(6-cyano-5-trifluoromethylpyridine -3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5 -yl]-2-fluoro-N-methylbenzamide is a potent CYP2C8 or C (b) a drug that is a CYP3A4 inhibitor, (c) a drug that is a CYP3A4, CYP2C19, or CYP2 Drugs metabolized primarily by C9, (c) UDP-glucuronosyltransferase ( (d) a drug that is a substrate of a UGT, or (e) P-glycoprotein, BCRP, or OATP1 In certain embodiments, 4-[7-(6-cyano-4-methyl-2-oxo-2-methylpropional] ... (5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7 -diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide is not administered concomitantly with drugs that are strong CYP2C8 or CYP3A4 inhibitors. In embodiments, 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl) -8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2 -Fluoro-N-methylbenzamide inhibits CYP3A4, CYP2C19, and CYP2C In certain embodiments, 4-[7-( 6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo -5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzene Zuamide is a drug that is a substrate of UDP-glucuronosyltransferase (UGT). not co-administered, or (d) a substrate of P-glycoprotein, BCRP, or OATP1B1 It is not administered in combination with drugs that

[0155] A non-limiting example of a strong CYP2C8 inhibitor is gemfibrozil.

[0156] Non-limiting examples of strong CYP3A4 inhibitors include boceprevir, aprepitant, clarithromycin, and fluticasone. Rithromycin, conivaptan, grapefruit juice, indinavir, lopinavir , itraconazole, mibefradil, ketoconazole, nefazodone, ritonavir, posa Conazole, nelfinavir, saquinavir, posaconazole, nelfinavir, saquinavir tetraprevir, conivaptan, telaprevir, boceprevir, telithromycin, clarithromycin fluconazole, voriconazole, clotrimazole, diltiazem, erythromycin, Examples include acetaminophen, verapamil, and troleandomycin.

[0157] Non-limiting examples of moderate to strong CYP3A4 inducers include avasimibe, centaminium, Jones wort, carbamazepine, efavirenz, phenytoin, etravirine, bolus Sentan, nafcillin, rifampicin, modafinil, rifabutin, and barbiturates Examples include phosphate salts.

[0158] A non-limiting example of a drug that is primarily metabolized by CYP3A4 is midazolam. A non-limiting example of a drug that is primarily metabolized by P2C19 is omeprazole. A non-limiting example of a drug that is primarily metabolized by P2C9 is S-warfarin.

[0159] A non-limiting example of a drug that is a substrate of P-glycoprotein is fexofenadine.

[0160] A non-limiting example of an agent that is a substrate of BCRP is rosuvastatin.

[0161] A non-limiting example of a drug that is a substrate of OATP1B1 is rosuvastatin.

[0162] In another embodiment, a method for treating metastatic castration-sensitive prostate cancer in a human male is provided. Thus, the method includes (a) determining whether a human male has metastatic castration-sensitive prostate cancer. and (b) using antiandrogens to treat metastatic castration-sensitive prostate cancer. and administering to a human male in an amount of 100 mg or more of a compound comprising, consisting of, or consisting essentially of the compound. and the antiandrogen is 4-[7-(6-cyano-5-trifluoromethylpyridine- 3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5- yl]-2-fluoro-N-methylbenzamide, 4-(3-(4-cyano-3-(trimethylsilyl) (Fluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazol 4-[7-[4-cyano- 3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazas pyro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide, or N- {(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole-1- yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3- The method of claim 1, wherein the compound is a carboxamide.

[0163] Treatment methods involving approved formulations A method for treating metastatic castration-sensitive prostate cancer in a human male, comprising administering apalutamide The approved formulation containing the compound was administered to human males with metastatic castration-sensitive prostate cancer. Also provided herein are methods that include administering the amount described in the package insert. In some embodiments, the approved formulation containing apalutamide is an ANDA formulation, an additional indication, In certain embodiments, the method is a clinically approved formulation. In certain embodiments, the method is clinically proven to be safe and / or effective. In certain embodiments, the method is clinically effective. It has been proven that:

[0164] The term "formulation" or "approved formulation" refers to a formulation approved by a government agency, e.g., the U.S. Food and Drug Administration or other active pharmaceutical ingredients with marketing authorization for at least one indication by a similar agency in the country It is a product that contains medicinal ingredients.

[0165] Similarly, a "label" or "package insert" is a document that provides relevant information about a drug product to the patient. Such information includes drug description, clinical pharmacology, indications ( Use of the preparation), contraindications (people who should not take the preparation), warnings, precautions, adverse events (side effects) Use), drug abuse and dependence, dosage and administration, use during pregnancy, use in nursing mothers, children and elderly patient use, drug delivery methods, patient safety information, or any combination of these. In certain embodiments, the label may be one or more of the following: The drug or product package insert provides instructions for use in patients with metastatic castration-sensitive prostate cancer. In a further embodiment, the label or product insert provides a label or product information approved by a regulatory agency. In yet another embodiment, the label identifies apalutamide as the chemical component. Superior efficacy in improving radiological progression-free survival or overall survival compared to In yet a further embodiment, the label includes data regarding whether the patient has metastatic pre-castration sensitive disease. If you have prostate cancer, you or your doctor will tell you to take apalutamide.

[0166] The term "Reference Listed Drug (RLD)" refers to new generic The formulations to be compared to demonstrate bioequivalence are 21 CFR 314 .3(b)) and by a Member State of the European Union or on the basis of a complete dossier. Based on Articles 8(3), 10a and 10b of Directive 2001 / 83 / EC, namely or approved for sale by the Commission upon submission of quality, preclinical and clinical data pursuant to Article 10c. Drugs that have been granted marketing authorization and are applying for marketing authorization for generic / hybrid drugs However, by demonstrating bioequivalence, usually through the submission of appropriate bioavailability studies, This is the medicine to be referred to.

[0167] In the United States, companies seeking approval to market generic equivalents must submit their Abbreviated New Drug Application (ANA) The RLD must be referenced in the Abbreviated New Drug Application (ANDA). For example, an ANDA applicant may be required to demonstrate that a previously approved drug product, i.e., an RLD, is safe and effective. The FDA has relied on its findings to determine whether the proposed generic formulation is RL. It is necessary to demonstrate in a specific way that the product is the same as D. Specifically, The drug product submitted in the ANDA must contain, among other things, the same active ingredient(s), use(s) as the RLD. It must have the conditions, route of administration, dosage form, strength, and package insert (with specific tolerances). An RLD is a listed drug, for which an ANDA applicant submits its proposed The ANDA formulation may be designed to meet, among other characteristics, the active ingredient, dosage form, route of administration, strength, additives, It is necessary to indicate that the accompanying documents and terms of use are the same. The Orange Book has a section on RLDs and a section on reference standards. In this case, RLDs and reference standards are identified by specific symbols. For ANDAs based on the FDA, the reference list drug is generally an approved The drug is a listed drug referenced in the compliance claim.

[0168] The reference standard is a formulation selected by the FDA and applicants seeking approval of an ANDA must , should be used to conduct the in vivo bioequivalence studies required for approval. The DA generally covers the in vivo bioequivalence studies that an ANDA applicant should use. Typically, the FDA selects a single reference standard for a drug. However, in some cases (e.g., when a reference drug is withdrawn from the market and Cases where the FDA determined that a drug was not withdrawn for safety or effectiveness reasons, and In the case of the FDA selecting an ANDA as the reference standard, what are the reference list drugs and reference standards? , may differ.

[0169] FDA defines Prescription Drug Product, OTC Drug Product and Discontinued Drug Product List In ts, the reference list drug is identified. The list drug identified as the reference list drug is: Represents a drug product on which an applicant seeking approval of an ANDA may rely. FDA, as appropriate, Prescription Drug Product, OTC Drug Produ ct, and Discontinued Drug Product Lists It is planned to periodically update the identified reference list of drugs.

[0170] FDA also regulates prescription drug products and OTC drugs. Reference standards are also identified in the Product Lists. The drugs listed have not undergone any in vivo bioequivalence studies required for approval. Represents FDA's best judgment at the time regarding an appropriate comparator for purposes of conducting the study. It is something.

[0171] In some cases, the FDA has not designated the listed drugs as reference listed drugs. If the applicant does not have a copy of the drug, such a listed drug may be protected from generic competition. If the FDA has not established a reference list for a drug product intended for , they can ask the FDA to establish a reference drug list for their formulation.

[0172] FDA may select new reference standards on its own initiative and, by doing so, For example, the listed drugs currently selected as reference standards have other characteristics besides safety and efficacy. When a drug is withdrawn from the market for a reason, a generic drug application is submitted and evaluated. This helps ensure that

[0173] In Europe, applicants must submit a written application for their generic / hybrid pharmaceutical product. This includes the ANDA or supplemental NDA (sNDA) formulation, the Reference Drug Product ( product name, strength, dosage form, MAH, first authorisation, Member State / Community) and is synonymous with RLD: 1.Medicinal products that are authorized or licensed in the EEA and are subject to European pharmaceutical legislation This will be used as the basis for indicating that the prescribed data protection period has expired. Pharmaceutical products are identified for the purposes of calculating the expiry of the data protection period and are generic / high-grade The drug product may have a different strength, dosage form, route of administration, or labeling than the hybrid drug product. stomach. 2. Generic / hybrid application file (product name, strength, pharmaceutical form, MA H, marketing authorization number) is cross-referenced to the medicinal product. This reference medicinal product is A drug product licensed under a different name and under a separate procedure, specified for purposes of calculating expiration In principle, the product information of this reference drug product is It serves as a basis for product information that draws attention to hybrid pharmaceutical products. 3. Pharmaceutical products used in bioequivalence studies (product name, strength, dosage form, MAH, supplier) Member States of the EU) (where applicable).

[0174] The different abbreviated approval pathways for drug products under the FD&C Act are listed in Chapter 505 of the FD&C Act. (j) and 505(b)(2) (21 U.S.C. 355(j) and ...b)(2), respectively). This includes the abbreviated approval pathway described in SC23 355(b)(2).

[0175] The FDA (the contents of which are incorporated herein by reference) is available at https: / / www .fda.gov / downloads / Drugs / GuidanceComplia nceRegulatoryInformation / Guidances / UCM57 According to the FDA, NDAs and ANDAs are divided into the following four categories: It is possible. (1) A "stand-alone NDA" is an NDA under section 505(b)(1) of the FD&C Act. 505(c) filed in the has been made or performed on behalf of the applicant, or to which the applicant has a right of reference or use, Full reports of safety and efficacy studies are included. (2) A 505(b)(2) petition is filed under section 505(b)(1) of the FD&C Act. The NDA was issued and approved under Chapter 505(c), which includes a safety and efficacy study. The complete audit report is included, and at least some of the information required for approval is provided by the applicant. was not carried out by or for the applicant, or or derived from a test for which the right to use has not been obtained. (3) An ANDA is a drug product submitted and approved under chapter 505(j) of the FD&C Act that: An ANDA is an application for a replication of a previously approved drug product. That is, relying on the FDA's finding that a Reference Listed Drug (RLD) is safe and effective. An ANDA generally includes a statement that the proposed generic product (a) is a generic product with the same active ingredient, conditions of use, and The same as the RLD in terms of condition, route of administration, dosage form, strength, and package insert (with certain tolerances). and (b) information to demonstrate that the RLD is bioequivalent to the RLD. The information must include the fact that testing has been conducted to demonstrate the safety and effectiveness of the proposed product. If necessary, the ANDA cannot be submitted. (4) The ANDA submitted is a drug that differs from the RLD in dosage form, route of administration, strength, or active ingredient. ANDA for a class of drugs (for products with two or more active ingredients) and FD A filed a complaint under section 505(j)(2) of the FD&C Act (compliance complaint). In response to the request, the studies are necessary to demonstrate the safety and effectiveness of the proposed product. It was determined that there was no

[0176] The scientific premise underlying the Hatch-Waxman Amendments is Section 505 of the FD&C Act. (j) to deem a drug product approved in an ANDA to be therapeutically equivalent to its RLD. Products classified as therapeutically equivalent are those that are interchangeable and The substituted product performs identically to the prescribed product when administered to a patient under the conditions specified in the accompanying documentation. In contrast to ANDAs, 5 § 05(b)(2) petitions are more flexible regarding the characteristics of the product being filed. 05(b)(2) applications are rated as therapeutically equivalent to the listed drug referenced at the time of approval. There is no need to be.

[0177] The term "therapeutically equivalent to a reference-listed drug" means that a formulation is therapeutically equivalent to the reference-listed drug. Generic equivalents, i.e., pharmaceutical equivalents, and therefore not covered by the FDA. are rated as AB therapeutic equivalents to the referenced products, thereby reducing actual or potential Bioequivalence issues support in vivo and / or in vivo bioequivalence equivalents. This means that the issue has been fully resolved with in vitro evidence.

[0178] "Pharmaceutical equivalent" means a product containing the same active pharmaceutical ingredient in the same amount as the reference listed drug. It refers to a formulation of the same dosage form and route of administration.

[0179] FDA classifies products as therapeutically equivalent if they meet the following general criteria: (1) their (2) they are approved as safe and effective; (a) they are in the same dosage form; (b) contain the same amount of the same active pharmaceutical ingredient in the same dosage form and route of administration; or other applicable standards of strength, quality, purity, and identity (3) they are (a) subject to known or potential bioequivalence questions; (b) that such a product meets acceptable in vitro standards without demonstrating any problems; If a product shows known or potential problems, it should be evaluated to ensure that it meets the appropriate bioequivalence criteria. (4) they are appropriately labeled; and (5) These are Current Good Manufacturing Practices Manufactured in compliance with regulations.

[0180] The terms "bioequivalent" or "bioequivalence" refer to pharmaceutical equivalents or pharmaceutical substitutes. The active ingredient or active moiety in When administered at a dose, the rate or extent to which the drug becomes available at the site of action is significant. Section 505(j)(8)(B) of the FD&C Act provides for testing and reference List describes a set of conditions under which drugs should be considered bioequivalent. The rate and extent of absorption were measured under similar experimental conditions using either single or multiple doses. When the therapeutic ingredient is administered in the same molar dose, [see] the absorption rate and extent of the drug or the degree of absorption of the test drug is not significantly different from that of a single dose or multiple doses. The therapeutic components were administered in the same molar dose under similar experimental conditions in either the single dose or single dose. When the drug is taken, there is no significant difference in the degree of absorption of the drug. The difference in drug absorption rates is intended and reflected in the proposed package insert; It is not essential to achieve effective body drug concentrations with chronic use and is not pharmacologically significant for the drug. is considered not to exist.

[0181] If these above methods are not applicable (e.g., if the product is not intended to be absorbed into the bloodstream), other scientifically valid, in vivo studies to demonstrate bioequivalence. In vivo or in vitro test methods may be appropriate.

[0182] For example, bioequivalence is particularly important when such in vitro studies are used to validate in vivo studies in humans. In vitro bioavailability data correlates with in vivo bioavailability data. In other situations, bioequivalence can be demonstrated using controlled clinical trials. Or it can be demonstrated by pharmacokinetic studies.

[0183] Further, the present specification defines a drug as being clinically proven to be safe and clinically effective. 1. A pharmaceutical product comprising apalutamide in an amount certified by the manufacturer, wherein the pharmaceutical product is packaged in a packaging and the packaging (a) identifies apalutamide as a regulatory approved chemical ingredient; and (b) indicating the use of apalutamide in the treatment of metastatic castration-sensitive prostate cancer. In certain embodiments, the label indicates that the product is a pharmaceutical product containing a label. , data to improve progression-free survival and / or overall survival by radiological imaging In certain embodiments, the label may include adverse reactions such as ischemic cardiovascular events, bone marrow events, and the like. In certain embodiments, the label lists the following as compared to standard of care: Include data showing an increase in ischemic cardiovascular events, fractures, falls, or stroke. In this form, the standard treatment is the administration of androgen deprivation therapy.

[0184] As used herein, unless otherwise specified, the term "safe" means a drug that is free from undue adverse side effects. The term "non-toxic, non-irritating, non-allergic, non-competitive" means that the present invention is free from When used in a manner consistent with a reasonable benefit / risk ratio, unless otherwise specified, The term "effective" refers to the ability of a compound to treat metastatic castration-sensitive prostate cancer when administered at a therapeutically effective dose. In certain embodiments, the present invention provides a method for treating a patient with a steroid hormone receptor agonist (SHR) that is effective in treating a patient with a steroid hormone receptor agonist (SHR). The methods described herein are safe. In other embodiments, the methods described herein are effective. In further embodiments, the methods described herein are safe and effective. In still further embodiments, a therapeutically effective amount of apalutamide is safe. In another embodiment, a therapeutically effective amount of apalutamide is safe or It is effective.

[0185] As used herein, unless otherwise specified (either independently or in conjunction with the term "safe" The term "clinically proven" (and / or used to modify "effective") is used in the Phase III or IV clinical trials sufficient to meet the Food and Drug Administration's approval criteria, or This means that evidence has been provided by similar studies for market authorization by the MEA. Preferably, an adequately sized randomized trial will be conducted to clinically demonstrate the efficacy of apalutamide. A placebo-controlled, double-blind study is used. Most preferably, it is used to treat metastatic castration-sensitive prostate cancer. To clinically prove the efficacy of apalutamide for The results of apalutamide plus steroid therapy were based on patient status as assessed by progression-free survival or overall survival. It was a randomized, placebo-controlled, double-blind trial of androgen deprivation therapy versus androgen deprivation therapy. For example, evidence can be provided by the clinical trial described in Example 1.

[0186] As used herein, unless otherwise specified, the term "clinically proven effective" is used interchangeably with "clinically proven effective" or "clinically proven effective." "was" means that the effectiveness of the treatment has been statistically significant in a Phase III or Phase IV clinical trial. It has been proven that the results of clinical trials are unlikely to be accurate at an alpha level of less than 0.05. or the clinical efficacy results do not meet the U.S. Food and Drug Administration approval criteria or This means that it is sufficient to meet similar tests for market authorization by the EMEA. For example, as specifically shown in the examples, placebo + androgen deprivation therapy Improved radiological progression-free survival and overall survival compared with patients treated with MRI. Apalutamide is administered orally at a therapeutically effective dose of 240 mg and is used in combination with androgen deprivation therapy. When administered in combination, the methods are clinically effective in treating patients with metastatic castration-sensitive prostate cancer It was proven to be.

[0187] As used herein, unless otherwise specified, the term "clinically proven safe" is used interchangeably with "clinically proven safe" or "clinically proven safe." "was" refers to a Phase III or IV clinical trial in which the treatment was confirmed based on analysis of the trial data and results. The safety of the treatment has been proven, the treatment is free of excessive side effects, and it meets the standards for approval by the U.S. Food and Drug Administration. is Europe, the Middle East, and Africa (EMEA) A statistically significant clinical benefit (effectiveness) sufficient to satisfy similar trials for market approval by For example, as specifically shown in the examples, Lutamide is administered orally at a therapeutically effective dose of 240 mg and is administered concomitantly with androgen deprivation therapy. When administered, it is clinically safe for the treatment of patients with metastatic castration-sensitive prostate cancer. was proven.

[0188] Sales method Provided herein is a method for marketing an approved formulation containing apalutamide, The method may include, consist of, or involve selling such a formulation. The reference list for such preparations consists essentially of the following: In certain embodiments, the formulation comprises instructions for treating castration-sensitive prostate cancer. It is a DA formulation, a label supplemental application formulation, or a 505(b)(2) formulation.

[0189] The term "sale" or "to sell" refers to the sale of a formulation, e.g., a pharmaceutical composition or oral dosage form, to a distributor. means the transfer of the property from the buyer to the buyer.

[0190] 1. A method of offering for sale an approved drug product comprising apalutamide, the method comprising: whether it involves making an offer to sell such preparations or consists in making an offer to sell such preparations or making an offer for sale, and The product package insert includes instructions for treating metastatic castration-sensitive prostate cancer, In certain embodiments, the formulation is an ANDA formulation, a supplemental indication application, It is a 505(b)(2) formulation.

[0191] The term "offering for sale" refers to formulations, e.g., pharmaceutical compositions and oral dosage forms, It means an offer to sell by a seller to a buyer.

[0192] In another aspect, there is provided a method of marketing apalutamide, the method comprising distributing apalutamide. A process involving, consisting of, or consisting essentially of placing on a conveyance apalutamide is used to treat metastatic castration-sensitive prostate cancer The methods described herein include a package insert containing instructions for safe and effective treatment. do.

[0193] In yet a further aspect, there is provided a method of offering apalutamide for sale, the method comprising: Including, consisting of, or resulting from placing apalutamide in distribution 10. A method consisting essentially of: The method includes a package insert containing instructions for safely and effectively treating susceptible prostate cancer. As described in the specification. [Example]

[0194] These examples are not intended to limit the scope of the claims provided herein, but are illustrative. Provided for illustrative purposes only.

[0195] Example 1: A randomized controlled trial of steroid hormone-sensitive prostate cancer (MSC) in subjects with metastatic hormone-sensitive prostate cancer (mCSPC). Palutamide plus androgen deprivation therapy (ADT) versus ADT in a phase 3 randomized, placebo-controlled, double-blind study Examination the purpose Main purpose The addition of apalutamide to androgen deprivation therapy (ADT) has been shown to improve the efficacy and safety of patients with mCSPC. Radiographic progression-free survival (RPFS) demonstrated superior efficacy in improving rPFS or overall survival (OS) To determine whether to provide

[0196] Secondary Objectives Delayed progression of pain and prostate cancer, skeletal-related events, and need for cytotoxic chemotherapy Clinically relevant results from the addition of apalutamide to ADT, including the use of opioids for sexual intercourse To evaluate the improvements you make; - To characterize the safety of adding apalutamide to ADT in subjects with mCSPC To evaluate; Population pharmacokinetics (PK) and pharmacodynamics of apalutamide namics, PD) to characterize; When used alone or in combination with apalutamide, leuproreductase To evaluate the PD effect of leuprolide on testosterone levels, eye; Apalutamide for the subpopulation of subjects with low-volume or high-volume mCSPC To evaluate the therapeutic efficacy of adding cefotaxime to ADT.

[0197] Other purposes • To evaluate exploratory biomarkers that predict response and resistance to treatment; Symptoms (i.e., pain, fatigue, urinary) and function (i.e., physical, emotional, social) to assess patient-related outcomes, including quality of life (e.g., clinical, behavioral, and physical), and health-related quality of life; Other clinically relevant endpoints of apalutamide + ADT compared with ADT alone To evaluate improvements in the Medical resource utilization that can be used for future economic modeling To collect data on utilization (MRU).

[0198] Study design The test described in Example 1 was performed at least in part according to the criteria described herein. This is a significant improvement over the previous study, which has been completed and is ongoing. A randomized, double-blind, placebo-controlled, multinational, multicenter study to determine whether participants benefited from This was a three-center, phase 3 trial. The data presented herein as they relate to this trial are not intended to be used as a substitute for the The data reflect the state of the study at the time of application. The study was conducted at 260 centers in 23 countries. Review boards at all participating institutions approved the study and it conformed to current pharmaceutical regulations for good clinical practice. The study was conducted in accordance with the guidelines of the International Conference on Harmonisation of Clinical Trials and the principles of the Declaration of Helsinki. provided written informed consent. The independent data monitoring committee was The study is being conducted by a research group appointed by the NIH. The NIH will monitor safety and efficacy prior to unblinding and will make recommendations for study conduct. Data was transferred from source documents to sponsor-prepared electronic case report files by staff at each site. The results were transcribed into the notification form. The randomization code must be kept confidential by investigators, patients, study site personnel, and other personnel until a clinical need is identified. and maintained blinding of the sponsor research team.

[0199] Approximately 1,000 subjects were planned to be enrolled in the study. Subjects who met the inclusion criteria and did not meet any of the exclusion criteria had a Gleason score (≤7) at diagnosis. >7), region (North America [NA] and European Union [EU] vs. other countries), and prior docetaxel The data were stratified by use of the tool (yes vs. no).

[0200] Patients were treated with apalutamide (240 mg) orally once daily in addition to continuous ADT. Patients were randomized 1:1 to receive either glioma or a matching placebo. Lawson score (≤7 vs. >7), region (North America and the European Union vs. all other countries), and preceding decade Patients were stratified by cetaxel treatment (yes vs. no). A screening period confirmed study eligibility. Subjects were not allowed to continue treatment for disease progression or intolerance. on 28-day cycles during the treatment period until the occurrence of unrelated treatment-related toxicity or termination of the study by the sponsor. Subjects will / have received treatment. If there was / was an exacerbation and alternative therapy was / was not initiated, clinical progression Treatment may continue until adverse events are observed, and subjects may continue treatment based on protocol-specified criteria. Study drug must be discontinued upon documented clinical progression. After discontinuation of study drug, subjects Patients will attend the end-of-treatment visit within 30 days of their last dose of study drug. Data collection (every 4 months) was conducted on the first and subsequent treatments for prostate cancer. secondary endpoints, dates, and type of disease progression (radiographic, PSA, clinical, or The data collection at follow-up will include additional data on survival for the The collection will be delayed if the subject dies, withdraws consent, becomes lost, or becomes untraceable. The study will continue until the trial is terminated by the sponsor. I SF), Brief Fatigue Inventory (BFI), and EQ-5D- 5L patient-report outcome (PRO) measures were also performed after treatment discontinuation. Follow-up will continue for up to 12 months. Either interim or final analysis If either test results are positive, all subjects will be considered for the duration of treatment if the subject is taking the active drug. The opportunity to enter a long-term open-label period, which will allow patients to take the drug (apalutamide) for approximately three years. The meeting will be held.

[0201] Subjects will be enrolled in the study starting from the signing of the informed consent and 30 days after the last dose of study drug. Safety was / will be monitored until after the study. Adverse events, including AEs, were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI). Cancer Institute-Common Terminology Criteria for Adverse Events, NCI-CTC AEs will be graded and summarized using version 4.03. Dose changes will be reported to the This will / was done according to the dose modification rules outlined in the protocol.

[0202] Figure 1 shows a diagram of the study design.

[0203] Study population Each potential subject must meet all of the following criteria to be enrolled in this study: there was. Patient Eligibility Overview Eligible patients had a bone scan with or without visceral or lymph node involvement. Have confirmed adenocarcinoma of the prostate and distant metastatic disease documented by one or more lesions All patients were required to meet Eastern Cooperative Oncology Group performance standards. The patient's disability status (a 5-point scale in which the higher the number, the greater the disability) was 0 or 1. Patients were castration-sensitive (i.e., patients not receiving ADT at the time of progression). Prior therapy for RA included prior docetaxel (up to 6 cycles, during treatment or prior to randomization) no evidence of progression), ADT for metastatic castration-sensitive prostate cancer for 6 months or less, or local Limited to total prostate cancer duration of 3 years or less. Radiation for symptoms related to metastatic disease. One course of chemotherapy or surgery, and other local treatments (e.g., radiation therapy, prostatectomy) ) had to have been completed at least one year prior to randomization. Patients receiving a tropin-releasing hormone agonist were not required to have received a first-generation Taking antiandrogens (i.e., bicalutamide, flutamide, or nilutamide) Antiandrogens had to be discontinued before randomization. Predisposition to severe angina, myocardial infarction, congestive heart failure, arterial / venous thromboembolic events, and stroke Patients with a history of or recent ventricular arrhythmia were excluded.

[0204] Inclusion criteria Subjects must be 18 years of age (or have consented in the jurisdiction where the study is being conducted) Must be male (of legal age); • Investigator-confirmed diagnosis of prostate adenocarcinoma; Technetium-99m (99m Tc) Distant metastatic disease demonstrated by one or more bone lesions on bone scan. Subjects with bone lesions were randomly assigned to undergo computed tomography (CT) or magnetic resonance imaging (MRI). Bone metastasis must be confirmed by chemotherapy. All patients were enrolled in the Eastern Cooperative Oncology Group up, ECOG) PS grade 0 or 1; Androgen deprivation therapy (i.e., medical or surgical castration) was not initiated within 14 days of randomization. GnRH agonists must be started within 28 days before randomization. Subjects were required to have been taking a first-generation antiandrogen for at least 14 days prior to randomization. Antiandrogens must be discontinued prior to randomization. Subjects were castration-sensitive and docetaxel-treated subjects met the following criteria: It must be. a.Received up to 6 cycles of docetaxel therapy for mCSPC; b. Received last dose of docetaxel within 2 months prior to randomization; c. Before randomization, investigator assessment of imaging and PSA showed a significant difference in response to docetaxel. Response was sustained stable or improved disease; • able to swallow tablets of all study medications; - To avoid the risk of drug exposure through semen (even in men who have had a vasectomy) Subjects were to use condoms during sexual intercourse while receiving study drug and for 3 months after the last dose of study drug. Sperm donation is prohibited during study drug administration and for 3 months after the last dose of study drug. Not allowed. Each subject will participate in the study after understanding the purpose of the study and the procedures required for it. Informed consent form showing willingness Subjects must sign the ICF. Subjects must comply with the prohibitions and restrictions specified in this protocol. The organization must be willing and able to adhere to the limitations. Other possible prior treatments for mCSPC: a. Up to one treatment unit of radiological or surgical intervention due to metastatic disease and one year prior to randomization Other local treatments completed prior to randomization; radiotherapy for metastatic disease was completed prior to randomization. To do; b. 6 years prior to randomization for mCSPC or localized prostate cancer with a total duration of 3 years or less ADT within months; Possible prior treatment for localized prostate cancer (all treatments >1 year prior to randomization) must be completed beforehand). a. ADT total within 3 years; b. All other prior therapies, including radiation therapy, prostatectomy, lymph node dissection, and systemic therapy A form of treatment.

[0205] Exclusion criteria Any potential subject who met any of the following criteria may participate in this study: and was excluded from • Pathologic findings consistent with small cell carcinoma, ductal carcinoma, or neuroendocrine carcinoma of the prostate; • known brain metastases; • Metastasis to lymph nodes only; • visceral metastasis (i.e., liver or lung) only; Other previous malignancies (sufficiently treated basal cell carcinoma or metastases) within 5 years prior to randomization Squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission anything other than); ●Laboratory test values ​​during screening: a.Hemoglobin < 9.0 g / dL; b. Neutrophils <1.5×109 / L; c. Platelets <100×109 / L; d. Total bilirubin >1.5 x upper limit of normal (ULN) [Note] : In subjects with Gilbert syndrome, if total bilirubin is >1.5 × ULN Direct bilirubin and indirect bilirubin were measured, and if direct bilirubin was ≤ 1.5 × ULN, Subjects may be eligible if: e. alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >2 .5×ULN; f. Serum creatinine >2.0 × ULN; g. Serum albumin <3.0 g / dL. Other next-generation antiandrogens (e.g., enzalutamide), CYP17 inhibitors (e.g., abiraterone acetate), immunotherapy (e.g., e.g., sipuleucel-T), radiopharmaceutical agents, or other treatments for prostate cancer; Bisphosphonates or denosumab for the management of bone metastases within 28 days prior to randomization Initiation of treatment with; Medications known to lower the seizure threshold must be discontinued or discontinued at least 28 days before randomization. is to be replaced; - Administration of other investigational therapies, blood product support, or growth factor support within 28 days prior to randomization or invasive surgical procedures (not including surgical castration), or currently enrolled in an investigational study ; Current or past treatment with antiepileptic drugs for the treatment of seizures (within 1 year prior to randomization). cerebrovascular accident, transient ischemic attack, or loss of consciousness; cerebral arteriovenous malformation; or edema or These include intracranial masses such as schwannomas or meningiomas causing mass effect, which a history of seizures or medical conditions that may predispose to seizures, including but not limited to: Current evidence of any of the following: a. Severe / unstable angina, myocardial infarction, or symptomatic congestive heart failure within 6 months prior to randomization overall, uncontrolled hypertension, clinically significant arterial or venous thromboembolic events (e.g., pulmonary embolism) ), or clinically significant ventricular arrhythmia; b. Gastrointestinal disorders affecting absorption; c. Systemic treatment of human immunodeficiency virus (HIV) active infection requiring treatment; d. Active or symptomatic viral hepatitis or chronic liver disease; ascites secondary to liver dysfunction or bleeding disorders; The subject has a known allergy, hypersensitivity, or intolerance to apalutamide or its excipients. To be resistant. Any condition or condition that, in the opinion of the investigator, would preclude participation in this study situation.

[0206] Treatment assignment Stratification and randomization procedures Gleason score at diagnosis (≤7 vs. >7), region (North America [NA] and European Union [E]) Subjects were stratified by prior docetaxel use (yes vs. no) and prior docetaxel use (yes vs. no). Subjects were randomly assigned in a 1:1 ratio to either the active treatment group or the control group. The distribution was counterbalanced by using randomly permuted blocks. Interactive web response systems (IWRS) involve subjects were assigned a unique treatment code indicating the treatment assignment and corresponding study drug kit. When contacting the IWRS, the requester must provide their user identification number and personal identification number. was used to provide relevant subject details to uniquely identify the subject.

[0207] Dosage and Administration Apalutamide administration Apalutamide was administered continuously, but planning study assessments and treatment compliance were not included. For purposes of this study, a treatment cycle is defined as 28 days. Subjects were randomly assigned to receive apalutamide or a matching sham. They were randomly assigned in a 1:1 ratio to receive one of the medications. Apalutamide 240 mg (4 x 60 mg tablets) once a day with or without food Taken orally once, or Placebo (4 tablets): Take orally once daily with or without food.

[0208] If a dose of apalutamide (or placebo) is missed, it should be omitted and replaced with the next dose the following day. The patient did not take the medication or any other medication.

[0209] Administration of ADT All subjects who did not undergo surgical castration received and continued a stable regimen of ADT. The choice of GnRHa (agonist or antagonist) was at the discretion of the investigator. Administration (dose and frequency) was consistent with the prescribing information.

[0210] Toxicity and rash management Table 1 summarizes apalutamide / placebo dose modifications for drug-related toxicities. The dose may be modified for any subsequent rash. If the dose is reduced due to drug-related toxicity , and further dose escalation was discussed with the sponsor.

[0211] [Table 1]

[0212] If the skin rash has any components of scaling, mucosal lesions, or pustules, apalutamide / pseudomonas aeruginosa should be administered. Drug treatment was discontinued, and the subject was referred to a dermatologist for diagnostic evaluation and (in addition to a dose change) skin If the skin rash is grade 3 or higher, the subject will be asked to submit a biopsy to a dermatologist with photographs. Further diagnosis by the doctor may require written consent.

[0213] Pre-study and concomitant treatments Permitted supportive care Supportive care medications are permitted according to institutional guidelines. is considered acceptable during testing. • Intermittent, short-term opioid analgesics are acceptable for pain control; Transurethral resection of the prostate (TURP) and surgical interventions such as placement of ureteral stents for management of complications due to local exacerbation. treatment; Bisphosphonates and denosumab for the management of bone-related metastases are approved in their respective markets. Subjects must be instructed to: During the above period, if such medication is being taken continuously or if exacerbation is confirmed by radiological imaging diagnosis You must agree not to begin such treatment until you have received a Bisphosphonates and denosumab in prophylactic doses are acceptable; • Conventional polysaccharide, selenium, and soy supplements; ● Blood transfusion and hematopoietic growth factors (blood product support and growth factor support) according to business guidelines (Note that no steroids were permitted for a period of 28 days or less prior to randomization); • Immunoglobulin therapy for non-cancer related treatment according to practice guidelines.

[0214] Prohibited Combination Therapies As a class effect, AR antagonists may have off-target mechanisms of action (γ-antibody). It is associated with seizures due to the inhibition of the aminobutyric acid chloride channel (GABAA). Drugs known to lower blood sugar or cause seizures are prohibited; a representative list is Included below: Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziplacid) hmm); ● Bupropion; ● Lithium; ● Meperidine (pethidine); Phenothiazine antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine) gin); Tricyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine) amine, maprotiline, mirtazapine); ● Aminophylline / theophylline; Other prohibited therapies include: • investigational drugs; • Abiraterone acetate or other CYP17 inhibitors; • Other hormonal agents for the treatment of prostate cancer; • other antitumor agents; Radiation therapy for new painful metastatic prostate cancer lesions not present on baseline imaging therapy; • 5-α-reductase inhibitors; ●Chemotherapy; • immunotherapy or vaccine therapy for cancer treatment; Other antiandrogens (e.g., bicalutamide, nilutamide, flutamide, cysteine ​​acetate) roterone, enzalutamide); Such treatment was initiated 28 days prior to randomization and the subject was continuing to take it. Bisphosphonates or denosumab for management of bone metastases, except in cases of osteoporosis. Tolerate preventive doses of bisphosphonates or denosumab; Systemic ketoconazole (or other azotoxins such as fluconazole or itraconazole) drugs); Diethylstilbestrol (DES) or similar; Pomegranate or pomegranate juice, which are thought to have endocrine effects on prostate cancer Other preparations such as saw palmetto; Radiopharmaceuticals such as strontium (89Sr) or samarium (153Sm) , or similar analogues such as radium-223 (223Ra); ●Spironolactone.

[0215] Prohibited concomitant medications The main drug interactions are summarized below. Strong CYP3A4 inducer: Potential for drug-drug interactions with apalutamide is clinically Not clinically tested. Potent inducers of CYP3A4 (e.g., phenytoin, carbapenem, Mazepine, rifampin, rifabutin, rifapentine, phenobarbital, ephedra Virenz, Tipranavir, St. John's Wort) should be avoided whenever possible. It won't happen. Apalutamide may also induce CYP3A4 and therefore has a narrow therapeutic index. Caution is advised when administered concomitantly with CYP3A4 substrates with multiple Strong CYP2C8 inhibitors (e.g., gemfibrozil) should be used with caution when administered with apalutamide. must be used in accordance with the Long-term use of systemic corticosteroids during the study is not permitted. In this case, short-term use (up to 4 weeks with tapering) and topically administered steroids (e.g., inhalation, topical, ocular, and intra-articular) are permitted.

[0216] Efficacy assessment / endpoint The progression of radiological imaging diagnosis is based on the revised Guidelines for the Evaluation of Treatment Efficacy in Solid Tumors (Revised ... Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Computed tomography (CT) / magnetic resonance imaging (MRI) for soft tissue lesions or bone scans Survival data were / will be assessed by progression of bone disease during the treatment period. were / will be collected throughout the study and during the follow-up period.

[0217] evaluation Computed tomography of the chest, abdomen, and pelvis during screening (within 6 weeks prior to randomization) Revised Guidelines for Assessment of Treatment Response in Solid Cancer Using Radiocontrast or Magnetic Resonance Imaging 1.1 Prostate Cancer Using Bone Scans During Cycles 3 and 5, and Every Fourth Cycle Thereafter Patients were assessed for efficacy according to Working Group 2 criteria. Scans from approximately 60% of patients were reviewed for independent central review. Adverse events were assessed monthly and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events. Grades were assessed using version 4.0.3. FACT-P assessment was performed on days 1 of cycles 2 to 7. were collected, then every other cycle, at the end of treatment, and every 4 months for up to 1 year after discontinuation. BPI-SF assessments were collected 6 days before each cycle, then at the end of each cycle, and as soon as treatment was discontinued. Data were collected every four months for a year.

[0218] More specifically, the efficacy assessment includes: • Tumor measurement (CT or MRI [abdomen, chest, and pelvis], 99mTc bone scan). The same imaging modality for tumor assessment was used throughout the evaluation of each individual subject. Pain not attributable to another cause should be assessed, and ECOG PS status grade should be signs of disease progression, including worsening of the condition or physical examination findings consistent with disease progression If suggestive signs or symptoms are documented, interim tumor evaluation and appropriate imaging should be considered. It won't happen. • Scans from approximately 60% of patients were randomly selected for independent central review; • Serum PSA assessment (performed in a central laboratory); Skeletal-related events (SREs) are symptomatic pathologic fractures, spinal cord compression, radiation to bone, or bone metastasis. defined as the occurrence of surgery for; Pain exacerbation was measured using the BPI-SF questionnaire at two consecutive assessments at least four weeks apart. was defined as a 2-point increase from baseline in the worst pain intensity (item 3) of the patient. and non-tapering of opioids or initiation of chronic opioids, whichever occurs first. The mean worst pain was greater than 4 in all subjects.

[0219] Patient-reported outcomes Patient-reported outcomes included the Brief Pain Questionnaire (BPI-SF), history of analgesic use, and simple Fatigue Scale (BFI), Cancer Treatment Prostate Function Assessment (FACT-P), and EQ-5D-5L (EuroQo to provide a simple general measure of health for clinical and economic evaluation) A standardized measure of health status developed by the EuroQoL Group (EuroQoL Group) These include the administration of a variety of questionnaires, including patient-reported outcomes. The questionnaires will be administered throughout the study and during follow-up (up to 12 months after treatment discontinuation) and over time. Data were / will be collected during the open-label period.

[0220] Tumor Response Criteria Defined according to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1) Imaging measurements were used to assess tumor response, as previously described. RECIST modified based on specific Prostate Cancer Working Group 2 (PCWG2) criteria Prostate-specific antigen measurements were assessed according to PCWG2 criteria. Therefore, rPFS was evaluated.

[0221] Patients in the embodied trials are required to comply with the revised Guidelines for Evaluation of Therapeutic Response in Solid Tumors. Efficacy was assessed according to the Prostate Cancer Working Group 2 criteria and the 1.1 version. The two Prostate Cancer Working Group 2 criteria for malignancy are: PSA: Initially, increase of 25% or more from baseline and increase of 2 ng / mL from worst state Addition (confirmed by a second reading after 3 weeks or more) ●Soft tissue lesions: Follow the guidelines for assessing the therapeutic response of solid cancers with provisos. Imaging must include at least a computed tomography scan or magnetic resonance imaging. and facilities with relevant expertise should perform endorectal magnetic resonance imaging or endorectal ultrasound. must be used. Report only changes in lymph nodes ≥2 cm in diameter at baseline. ○ Record changes in nodal and visceral soft tissue areas separately. Complete disappearance of disease at any site should be recorded separately. ○ Confirm favorable changes on the second scan. Use a waterfall plot to document the changes. A second scan should be performed 6 weeks or more later to confirm progression at the first evaluation. Bone: Appearance of two or more new lesions and at least two new lesions at the first reassessment A confirmatory scan taken more than 6 weeks later showing significant lesions.

[0222] endpoint Dual primary endpoints The coprimary endpoints were radiographic progression-free survival (rPFS) and overall survival (OS). Overall survival (OS) was

[0223] Secondary endpoints Secondary endpoints were time to cytotoxic chemotherapy, Brief Pain Questionnaire (BPI-S) F: Worst pain [item 3] was used during the time to pain exacerbation endpoint, with a score range of 0 ~10, with lower scores representing lower levels of pain intensity and a change of 2 being the minimally important difference. time to pain progression as assessed by the MRI scan, time to chronic opioid use, and time to skeletal-related events. Low-volume or high-volume metastatic castration-sensitive prostate Predefined subgroup analyses based on data from patients with cancer were planned. Evaluation of treatment outcomes in these groups was a secondary objective. The definition of high-volume disease was metastatic hominis Sweeney CJ, Chen YH, Carduc Adapted from Chemohormonal Therapy by i M, et al. N Engl J Med 2015;373:737-46 are as follows: 1) Visceral metastasis and 1 1) ≥ 1 bone lesion, or 2) ≥ 4 bone lesions with ≥ 1 bone lesion outside the axial skeleton. Volumetric disease was defined as the presence of bone lesions that did not meet the definition of high-volume disease.

[0224] Exploratory Endpoints Exploratory endpoints were time to prostate-specific antigen (PSA) progression and freedom from a second progression. The time to second progression-free survival was Whichever occurs first is the first time the patient has received their first subsequent therapy for prostate cancer. The first investigator-assessed disease progression during the study period or death from any cause. Time from randomization to the occurrence of 1 (PSA progression, imaging progression, or clinical progression) Health-related status was defined as the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. Patient-reported outcomes related to quality of life were assessed. FACT-P raw scores ranged from 0 to 156. FACT-P scores range from 0 to 10, with higher raw scores indicating better health-related quality of life. A change of 6 to 10 points in the TAL score is the minimally important difference.

[0225] Population pharmacokinetic evaluation Trough PK samples were / will be collected. Apalutamide and active metabolite Pre-dose blood samples for analysis of (JNJ-56142060) concentrations were collected on Days 2, 3, 4, and 6. Collected / will be collected on day 1 of cycles 5 and 6.

[0226] PK substudy of leuprolide Optional PK samples were taken from patients receiving leuprolide acetate as GnRHa at randomization. At least 60 consenting subjects (in selected countries) who have received or will receive the study The samples were collected / will be collected from For analysis of concentrations, samples were / will be collected on Day 1 of Cycles 1, 3, 4, 5, and 6. This becomes:

[0227] Biomarker evaluation Using plasma-based circulating DNA, androgen receptor (AR) ) Resistance to apalutamide assessed by assessing the presence of the F876L mutation and whole blood or plasma DNA Other markers that may be associated with the formalin in the archives have been evaluated / will be evaluated. Fixed paraffin-embedded (FFPE) tumor blocks or Tumor slides were collected to assess mRNA expression of genes representing AR signaling to identify high The biology of volumetric and hypovolemic disease was compared with the results, and genes such as OX40, GITR, and FOXP3 were included. The expression of immune markers was / will be evaluated.

[0228] Safety evaluation Safety assessment included AEs, vital signs (blood pressure), physical examination, and ECOG PS, hematology panel, serum chemistry panel, liver function tests, and fasting lipid panel. Clinical tests may include, but are not limited to, the following: Unscheduled laboratory tests were performed according to schedule at screening and during treatment. Vital signs and Eastern Cooperative Oncology Group performance status at each visit Safety was continuously evaluated, and adverse events were assessed according to the National Cancer Institute's Adverse Events Common Pathology. Grades were assessed according to the Terminology Criteria 4.0.3. FACT was assessed on Day 1 of Cycles 1 to 7. -P assessments will be collected every other cycle, at the end of treatment, and every 4 months for up to 1 year after discontinuation. did.

[0229] Electrocardiogram (ECG) An electrocardiogram (ECG) (12 leads) was recorded at screening.

[0230] Vital signs Body temperature, heart rate, respiratory rate, and blood pressure were recorded at screening. In this case, only blood pressure will be measured.

[0231] Physical examination The screening physical examination should include, at a minimum, a description of the subject's general appearance, height, weight, and skin tone. Includes skin examination, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system. During treatment and at EOT visits, limited symptom-specific physical examinations and weight Evaluation requested.

[0232] Eastern Cooperative Oncology Group (ECOG) PS If scheduled, the PRO survey will be administered before any other study procedures scheduled for the same day. ECOG PS assessment was performed as described above.

[0233] Subject Completion / Withdrawal completion Subjects who died or were lost to follow-up before the end of the study If the participant ceases to participate or withdraws consent, they will be considered to have completed the study.

[0234] Discontinuation of apalutamide If a subject's study drug must be discontinued before disease progression, this may result in withdrawal from the study. This does not result in automatic withdrawal of the subject. If the subject does not show any clinical progression by radiological imaging, If the patient has a progressive disease associated with clinical progression and an alternative therapy is not initiated, treatment should be continued until clinical progression is observed. It is also possible to detect radiological progression in subjects with evidence of clinical progression. Every attempt must be made to capture

[0235] However, a subject's study treatment must be discontinued for the following: ●Clinical deterioration is defined as follows: ●ECOG PS grade of 3 or higher (related to the progression of prostate cancer) Deterioration of - The following are due to tumor progression (even in the absence of radiological evidence of disease): You need to start one of them Subsequent anticancer therapy for metastatic prostate cancer Radiation therapy for metastatic prostate cancer lesion(s) (present at baseline) Palliative radiation to the lesion is not considered a clinical deterioration) • Surgical intervention for complications of metastatic prostate cancer progression. Chronic opioid analgesic need: For subjects entering the study without taking opioids, For this study, chronic opioid use was defined as ≥3 weeks for oral preparations or ≥1 week for parenteral preparations. It is defined as the administration of opioid analgesics for 7 or more consecutive days after the administration of opioids. For subjects entering trials with chronic opioid use, the Total daily dose of opioid analgesics for 3 weeks or more, or for parenteral preparations for 7 days or more Defined as an increase of 30% or more. Three or more dose level reductions for grade 3 or higher treatment-related AEs (Table 1) Any grade seizure or grade 4 neurotoxicity Treatments that are unblinded for any reason, except for the IDMC recommendation to unblind the trial, Subjects who were assigned to the treatment The investigator may discontinue study treatment for safety reasons (e.g., AEs). is in the subjects' best interests

[0236] Imaging studies at treatment interruption or EOT visit to assess radiological progression Every attempt should be made to obtain a diagnosis of radiological or clinical Subjects who experienced an increase in PSA in the absence of clinical progression continued / will continue study drug In this study, serial PSA measurements were performed, but no PSA data was collected due to disease progression or treatment discontinuation. Progression or change in PSA levels was not used as a marker for determining the outcome. If you discontinue but do not withdraw consent for tracking, scheduled assessments will be scheduled based on time and event. Follow-up should continue according to the schedule.

[0237] statistical methods Overview The clinical trial exemplified herein is designed to enroll approximately 1,000 patients. Radiographic progression-free survival was first examined. In this case, α was reused for overall survival based on a fallback method. A type 1 error was planned to detect a hazard ratio of 0.67 with a two-sided significance level of 0.005. To provide at least 85% power for the study, 368 imaging progression-free survival events were included. For the final overall survival analysis, a hazard ratio (HHR) with a two-sided significance level of 0.045 was required. To provide approximately 80% power to detect a ratio of 0.75, 410 deaths were Overall survival analysis was performed using the Wang-Tsiatis method with a shape parameter of 0.2. A group sequential design was incorporated with an α-spending function calculated as a power-law bound by Two interim analyses were planned for the time period. The first interim analysis was for the radiologically diagnosed progression-free survival. At the time of the primary analysis of adverse survival, approximately 50% of all events required for overall survival were included. The alpha level for the interim analysis for overall survival was The significance level was assumed to be 0.045, and the result was 0.009. Subgroup analysis revealed that the effect of treatment The coprimary endpoints were pre-specified to assess consistency. In this case, the secondary endpoints were evaluated using the following two-sided significance level α = 0.05: The following hierarchical order will be implemented: 1) Time to cytotoxic chemotherapy; 2) Increased pain; time to adverse events, 3) time to chronic opioid use, and 4) time to skeletal-related events. Demographic and baseline characteristics were summarized using descriptive statistics. The primary statistical method for comparison of the time endpoints in the The Kaplan-Meier product limit method and the Cox proportional hazards model were used. was used to estimate time-to-event variables and determine hazard ratios and associated confidence intervals. Ta.

[0238] Analysis population The primary analysis population was the intent-to-treat population, which included all randomized subjects. The ITT population will be used for subject allocation and efficacy analysis. The safety population consisted of patients who received at least one dose of study drug when treated. Includes all subjects who participated.

[0239] Determining sample size The overall type I error rate for this study was planned to be 5%. The co-primary outcome of OS with a significance level of 0.005 was assigned to the rPFS endpoint. The study will utilize a coprimary endpoint, with OS assigned a value of 0.045. A study is considered successful if at least one of the endpoints is statistically significant.

[0240] If radiologically significant progression-free survival was achieved, a fallback strategy was used. Using the method, the alpha level for radiological progression-free survival was compared with the overall survival. Approximately 50% (205) of all events required for overall survival analysis were discharged. What was likely observed in the primary analysis of progression-free survival by radiological imaging The alpha level for the interim analysis of overall survival was estimated to be 2-sided. The overall survival analysis showed that the mean risk of low or high volume tumors was 0.009, assuming a mean risk of 0.045. Further subgroup analysis of patients with volumetric disease is possible without assigned alpha consumption. The dual primary endpoints were overall survival and radiological progression-free survival. If the findings were statistically significant, the secondary endpoints were assessed using an α of 0.05 for each. The overall two-sided significance level will be performed in the following hierarchical order: 1) Cytotoxicity Chemistry 1) time to initiation of therapy; 2) time to pain exacerbation; 3) time to chronic opioid use; 4) Time to skeletal-related events. Demographic and baseline characteristics were analyzed using descriptive statistics. The data were summarized using the Kaplan-Meier product limit method and the Cox proportional hazards model. Estimate time-to-event variables and determine hazard ratios and associated confidence intervals using Regarding the radiological imaging progression-free analysis, radiological imaging progression or death was not included. Patients without evidence of death, or who withdraw from the study or develop new Patients who received new subsequent anticancer therapy were censored at the date of their last tumor assessment and were followed by baseline Patients without subsequent tumor assessment were censored at the date of randomization.

[0241] At a two-sided significance level of 0.005, the hazard ratio (HR) was 0.67 (control group [A rPFS was 20 months for the apalutamide + ADT group vs. 30 months for the apalutamide + ADT group Approximately 368 samples were used to provide at least 85% power in detecting the median It is estimated that rPFS events will be required. The study also included a control arm (ADT ) based on an expected median OS of 44 months for the co-primary endpoint of OS This provides sufficient power (approximately 80%) to detect a HR of 0.75. With an enrollment duration of 0 months (approximately 1,000 subjects), the expected Approximately 410 death events are required to detect a constant HR. This will result in a total trial period of approximately 54 months.

[0242] Efficacy analysis The Kaplan-Meier product limit method and Cox proportional hazards model were used to estimate the risk of event We will estimate the variables for the period and obtain the HR along with the associated confidence interval.

[0243] Interim analysis For the co-primary OS endpoint, the approximate total number of events required (410) After observing 60% (approximately 246 events) and approximately 75% (approximately 308 events), Two interim analyses are planned for this study. The timing of the first interim analysis of OS is This analysis may occur simultaneously with the primary analysis of rPFS. However, this analysis may not be consistent with the valid interim analysis of OS. The number of death events required for analysis was longer for the analysis of the rPFS endpoint. If a delay is deemed necessary, it may be performed at a different time. No interim analysis is planned for points.

[0244] Population PK and PD analysis Population PK analysis of plasma concentration-time data of apalutamide using nonlinear mixed-effects modeling When sufficient data are available, analyses will be conducted on efficacy and AE measures. The relationship between exposure to apalutamide and its active metabolite (JNJ-56142060) and It can be analyzed.

[0245] PK analysis of leuprolide Descriptive statistics of leuprolide PK data were obtained by treatment group (apalutamide or placebo) and The dose of leuprolide acetate alone or with apalutamide will be summarized. Statistical analysis will be performed to compare leuprolide concentrations when administered in combination The proportion of subjects with testosterone levels below 50 ng / dL varied by treatment group. It will be summarized descriptively.

[0246] Biomarker analysis The association of biomarkers with clinical response or time-to-event endpoints is Depending on the endpoint, appropriate statistical methods (analysis of variance, ANOV) A], categorical models, or survival models).

[0247] Safety analysis Safety parameters evaluated include the occurrence and severity of treatment-emergent AEs, the physical condition of the subjects, and Clinically significant changes in clinical laboratory findings, vital sign measurements, and laboratory test results. Exposure to study drug and reasons for discontinuation of study treatment will be collected.

[0248] result Overview 525 patients were randomized to apalutamide plus ADT and 527 to placebo plus ADT. The median age was 68 years, and 8% had received prior treatment for localized disease. 11% received prior docetaxel, 63% had high-volume disease, and 37% At the first interim analysis, with a median follow-up of 22.7 months, Apalta Midazolam significantly improved radiological progression-free survival (hazard ratio [HR] 0.01). .48; 95% confidence interval (CI), 0.39-0.60; P<0. .0001), and the risk of radiological progression or death was reduced by 52%. The risk of death was also improved with apalutamide, reducing the risk of death by 33% (HR, 0.6 7; 95% CI, 0.51-0.89; P=0.0053). Grade 3 / 4 adverse events The rates of refractory thyroid cancer did not differ between the apalutamide and placebo groups. Open labeling is recommended to allow patients receiving placebo to transition to apalutamide The addition of apalutamide to ADT improved overall survival in patients with metastatic castration-sensitive prostate cancer. The survival time and progression-free survival time as determined by radiological imaging diagnosis were significantly improved, and there was no difference between the placebo + ADT group and the placebo + ADT group. It had an unremarkable side effect profile.

[0249] patient 525 patients were randomized to apalutamide and 527 to placebo (Figure 1). At the time of the prespecified interim analysis, and in 83 patients in the apalutamide group and in the placebo group, After 117 deaths, the median follow-up period was 22.7 months. The values ​​were 23 for apalutamide and 19 for placebo (range 1 to 19 for each group). 37) The median treatment duration was 20.5 months for apalutamide and 18.3 months for placebo. At the time of discontinuation of treatment, 66% of patients in the apalutamide group and 10% of patients in the placebo group A total of 45 patients across the groups consented to study treatment. Withdrawn. Since these patients were followed up for survival and secondary endpoints, the data of these patients were not lost. A total of 39 patients either had unknown residences and could not be followed up or withdrew from further data collection. This information is not incorporated into Figure 1 in any other form.

[0250] For demographic characteristics and baseline disease characteristics, a good balance was achieved (Table 2). Patients had de novo metastatic castration-sensitive prostate cancer or recurrent metastatic disease after initial diagnosis of local disease. Most patients had de novo metastatic disease. The previous treatments

[0251]

Table 2-1

[0252]

Table 2-2

[0253] Prior treatments for prostate cancer are listed in Table 3.

[0254] [Table 3]

[0255] Dual primary endpoints Progression-free survival and overall survival according to radiological imaging 365 radiologically-based progression events were observed (134 with apalutamide) The 24-month event-free rate was 68% in the apalutamide group, Treatment with apalutamide was associated with no radiological findings of progression-free survival (ROF) compared with 48% in the placebo group. The adverse survival time was significantly improved (HR, 0.48; 95% CI, 0.39-0.60; P < 0.001). .0001), and the risk of radiological progression or death was reduced by 52% (Figure 2A). At the time of this final analysis for radiological progression-free survival, the median was Progression-free survival by radiological imaging was not reached with tamoxifen and was 22.1 months with placebo. The effect of apalutamide on duration was evaluated using a combination of factors including prior docetaxel use and disease volume. The benefit was consistent across analyzed subgroups (Figure 2B). Investigator assessment of progression was further confirmed by radiological imaging (concordance rate, 85%).

[0256] Treatment with apalutamide significantly improved overall survival (24-month event-free rate was 9.2%). The incidence rates were 82% in the apalutamide group and 74% in the placebo group, respectively. HR, 0.67; 95% confidence interval [CI], 0.51-0.89; P = 0.0053) The risk of death was reduced by 33% (Figure 3A). The treatment effect on overall survival was greater than that of placebo. Apalutamide was consistently favored by the study, and there was no difference in apalutamide efficacy based on disease volume. There was no difference (Fig. 3B).

[0257] Secondary endpoints Time to cytotoxic chemotherapy was significantly improved with apalutamide compared with placebo. Based on a pre-planned hierarchical test sequence, the time to pain progression was estimated (Table 4, Figure 4). This did not reach statistical significance, so further secondary endpoints were not considered. No formal testing was done.

[0258] [Table 4] NE, not calculated. * Pain exacerbation was reported by the patient using the BPI-SF Worst Pain (item 3). Scores ranged from 0 to 10, with lower scores indicating lower levels of pain intensity. represents the minimum important difference, and a change of 2 was the minimum important difference. †Secondary endpoints were tested in a preplanned hierarchical sequence. Pain If apalutamide is determined not to significantly improve the time to progression, further adverse events should be considered. Secondary endpoints were not formally tested. ‡Skeletal events include symptomatic lesional fracture, spinal cord compression, radiation to bone, or bone damage. The incidence of surgery was defined as the occurrence of surgery.

[0259] Other clinically relevant endpoints The median time to PSA progression was more favorable for patients receiving apalutamide compared with placebo. (Figure 5, Table 4), and PSA was significantly higher in 68% and 10% of patients in the apalutamide and placebo groups, respectively. Undetectable levels (PSA < 0.2 ng / mL) were achieved in 29% of patients. 87 patients in the apalutamide group and 190 patients in the placebo group had prostate cancer Patients who received subsequent treatment with apalutamide (first therapy listed in Table 5) were significantly more likely to receive apalutamide than placebo. The median progression-free survival (PFS) was improved by the treatment with EGFR (Table 4, Figure 6). There were no between-group differences in time to symptomatic local exacerbation (Table 4). Analysis of change in FACT-P from baseline using the model showed that maintained health-related The quality of life was shown to be no different between the groups (Figure 7).

[0260] [Table 5] * Possible reasons for discontinuation were disease progression, adverse events, patient request to discontinue, death, and physician This was a violation of the decision and protocol. †Docetaxel, abiraterone acetate plus prednisone, enzalutamide, cabazitaxel , radium-223, and sipuleucel-T. ‡Patients must be discontinued after discontinuation and first subsequent therapy to be eligible for enrollment in the next clinical trial. Previously unblinded. § Diethylstilbestrol, flutamide, and cyproterone. ** Etoposide, paclitaxel, estramustine, carboplatin, and cisplatin Chin is one example. *** These include zoledronic acid, clodronate, prednisolone, and prednisone. do.

[0261] safety Table 6 lists the most common treatment-emergent adverse events. Grade 3 and 4 events The incidence of adverse events (42.2% in the apalutamide group and 40.8% in the placebo group) and serious adverse events ( The incidence of rheumatoid arthritis was 19.8% in the apalutamide group and 20.3% in the placebo group, with no significant difference between the groups. Treatment discontinuation was due to progressive disease (99 [19%] apalutamide, 227 [ 43% (placebo, Table 5). Adverse events occurred in 42 (8.0%) patients in the apalutamide group. This resulted in 28 (5.3%) patient discontinuations in the placebo and control groups (Table 7). Ten (1.9%) patients in the mido group and 16 (3.0%) patients in the placebo group were , and death as a result of adverse events (Table 8). Rash of any grade was also observed in patients treated with placebo (8.5 % (Table 6), and The most common event associated with lutamide was any type of rash (6 Hypothyroidism was reported in 6.5% and 1.1% of patients in each group, respectively. All events were grade 1 or 2. Ischemic heart disease was reported in Apalta. Ischemic events were reported in 4.4% of patients in the rituximab group and 1.5% of patients in the placebo group. The drug led to death in two patients in each group.

[0262] [Table 6] Values ​​are numbers (%). * Rash is a classification term that includes skin eruption, erythema butterfly, erythematous eruption, exfoliative eruption, follicular eruption, Generalized rash, macular rash, maculopapular rash, papules, papular rash, pruritic rash, pustular rash, genital rash, blisters, skin exfoliation, exfoliative dermatitis, skin reactions, systemic lupus erythematosus rash, These include toxic skin eruptions, oral ulcers, drug eruptions, conjunctivitis, erythema multiforme, stomatitis, and urticaria. . †Fracture is a classification term and includes acetabular fractures, ankle fractures, clavicle fractures, femoral neck fractures, and femoral neck fractures. Thigh bone fracture, fibula fracture, foot fracture, forearm fracture, fracture, sciatica fracture, fracture pain, hand fracture, hip fracture , lower limb fractures, patella fractures, radius fractures, rib fractures, skull fractures, vertebral compression fractures, vertebral fractures, These include sternum fractures, thoracic spine fractures, tibia fractures, traumatic fractures, ulna fractures, upper limb fractures, and wrist fractures. can be done. ‡Hypothyroidism is a classification term and includes autoimmune thyroiditis, thyroid-stimulating hormone levels in the blood, These include increased blood sugar and hypothyroidism. § Seizure is a classification term that includes seizures and tongue biting.

[0263] [Table 7-1]

[0264] [Table 7-2]

[0265] [Table 7-3]

[0266] [Table 7-4]

[0267] [Table 8]

[0268] A post-hoc analysis considering the competing risk of death was performed based on the Fine & Gray model. (Table 9) Fine JP, Gray RJ. J Am Stat Assoc 1 999;94:496-509. Subdistribution hazard ratios of the apalutamide group compared with the placebo group Estimates are presented with their respective 95% confidence limits and P values ​​from Wald chi-square tests. The results of this post-hoc analysis supported and confirmed the results of the pre-planned analysis.

[0269] [Table 9]

[0270] Rash management Apalutamide-associated skin rash commonly presents as a generalized rash or a maculopapular rash. Treatment-emergent skin rash was reported in 8.5% of patients in the placebo group compared with 1.5% in the placebo group. Grade 3 rash was reported by 27.1% of patients in the apalutamide group. reported in patients treated with tamoxifen (6.3%) and placebo (0.6%). No cases of rheumatoid arthritis or toxic epidermal necrolysis were reported. Skin rash was not reported after apalutamide. In the 12 (2.3%) patients, treatment was discontinued and 28 (5.3%) patients had their dose reduced. 44 (8.4%) patients discontinued treatment, and 1 patient discontinued treatment in the placebo group. Treatment discontinuation occurred in 0.2% of patients, dose reduction occurred in 4 (0.8%) patients, and 5 (0.9%) patients. % of patients discontinued apalutamide treatment due to a grade ≥3 rash. Seven (1.3%) patients in the placebo group and one (0.2%) patient in the placebo group experienced steroid-induced ... For patients with skin rash, treatment included topical corticosteroids. These include steroids, oral antihistamines, systemic corticosteroids, medication interruptions, and dose reductions. The median time to onset of rash was 81 days in the apalutamide group and 10 days in the placebo group. It was 141 days.

[0271] Consideration In this Phase 3 study in men with metastatic castration-sensitive prostate cancer (mCSPC): Apalutamide plus ADT significantly improved overall survival and radiological imaging outcomes compared with placebo plus ADT. The reduction in risk of death varied based on disease volume. The benefit in progression-free survival from radiological imaging was not observed in patients with prior docetaxel. This was consistently observed across all subgroups analyzed, including patients with methicillin-resistant Staphylococcus aureus (MSA) exposure. A higher proportion of patients in the placebo group who discontinued treatment received subsequent life-prolonging therapy for prostate cancer. Despite this, 64 of 170 patients (38%) in the apalutamide group 165 of 271 patients (61%) in the placebo and apalutamide groups (Table 5) Based on the results from this first planned interim analysis, The National Data Monitoring Committee has confirmed that the transition of patients taking placebo to receiving apalutamide We recommended unblinding to ensure

[0272] Secondary endpoints included time to cytotoxic chemotherapy and time to second progression-free survival. The clinical and exploratory endpoints also favored apalutamide treatment. ADT also significantly increased the proportion of patients achieving undetectable PSA levels compared with placebo plus ADT. This example study showed that 10% of patients with PSA progression had a higher risk of developing PSA. Initial treatment with apalutamide in patients with metastatic castration-sensitive prostate cancer has been associated with clinical outcomes. This resulted in improved performance.

[0273] The trial is intended to include a broad range of patients with metastatic castration-sensitive prostate cancer. This resulted in relatively small specific patient subgroups. confirmed the survival benefit of docetaxel during informed consent, but only 11% Prior docetaxel was received before study enrollment. This may be due to the perceived These likely reflect differences in patient eligibility and patient preferences or care approaches. However, the consistency of clinical benefit of apalutamide across all subgroups was reaffirmed It has been done.

[0274] The rates of high-grade and serious adverse events were not different between the apalutamide and placebo groups. The rate of discontinuation due to adverse events was low in both groups. The safety profile of apalutamide was generally consistent with that of apalutamide. Rashes are common and are typically treated with antihistamines and topical glucocorticoids. The hypothyroidism was mild to moderate and was managed with cessation of treatment and dose reduction. The patient was monitored with stimulating hormones and managed with levothyroxine. Health-related quality of life was also improved. The mean mean HR was maintained at 1.25, with no significant differences between groups, supporting the tolerability of apalutamide plus ADT.

[0275] In conclusion, the exemplified study in patients with metastatic castration-sensitive prostate cancer showed high Patients with volumetric and low-volume disease, prior docetaxel, and prior treatment of localized disease Apalutamide A is administered to patients with apalutamide A, including those with previously diagnosed or de novo disease. Addition to DT was associated with a safety profile significantly different from placebo plus ADT and was associated with a significant improvement in health-related quality of life. It significantly improved overall survival and delayed disease progression while maintaining quality of life.

[0276] Formulation of apalutamide The apalutamide tablets supplied in this study contain 60 mg of apalutamide. were manufactured and provided under the responsibility of the sponsor.

[0277] The placebo was provided as a tablet formulation and was varied in size, color, and shape to maintain the blinded nature of the study. It will be matched.

[0278] packaging Apalutamide 60mg tablets are packaged in a 160cc high-density polyethylene container ( Packaged in a high-density polyethylene (HDPE) bottle with 120 pieces.

[0279] Example 2: FDA Final Approved Drug Product Package Insert FDA approves ERLEADA(TM) (Apalutamide) as a reference listed drug The following package insert for acetaminophen (Tamiflu) was approved on September 17, 2019.

[0280] Key parts of prescribing information These main parts contain all the information you need to use ERLEADA safely and effectively. does not include. See full prescribing information for ERLEADA. ERLEADA® (apalutamide) tablets for oral use First US Approval - 2018 Recent major changes Indications and Usage (1) September 2019 Warnings and Precautions (5) September 2019 Indications and usage ERLEADA is an androgen receptor inhibitor for the treatment of patients with: Applies to. ●Metastatic castration-sensitive prostate cancer (1) Non-metastatic castration-resistant prostate cancer (1) Dosage and Administration ERLEADA 240 mg (four 60 mg tablets) will be administered orally once daily. Swallow the tablet whole. ERLEADA can be taken with or without food. May (2.1) Patients also receive gonadotropin-releasing hormone (GnRH) analogs concomitantly. or have had both testicles removed. (2.1) Dosage form and content Tablets 60 mg (3) contraindications none. Warnings and Precautions Ischemic cardiovascular events occurred in patients taking ERLEADA. Monitor for signs and symptoms of cardiac disease. Optimize management of cardiovascular risk factors. 5.1). Fractures have occurred in patients taking ERLEADA. Evaluate and treat patients with bone-targeted agents according to established guidelines. (5.2) Falls occurred in patients taking ERLEADA, with an increased incidence in the elderly Assess patients for fall risk (5.3). Seizures occurred in 0.4% of patients taking ERLEADA. Permanently discontinue ERLEADA in patients who develop symptoms. (5.4) Embryo-fetal toxicity: ERLEADA may cause harm to the fetus. Advise men with female partners to use effective contraception (5.5, 8.1, 8.3) Adverse reactions The most common adverse reactions (≥10%) were fatigue, cardiac arrhythmia, rash, decreased appetite, falls, These include weight loss, high blood pressure, hot flashes, diarrhea, and bone fractures (6.1). To report a suspected adverse reaction, call 1-800-526-7736 (1-800-JA Call Janssen Products, LP at NSSEN or 1-800-FDA-1 Contact FDA at 088 or www.fda.gov / medwatch. Drug interactions - CYP3A4, CYP2C19, CYP2C9, UGT, P-gp, BCRP, or Concomitant use with drugs that are sensitive substrates of OATP1B1 results in decreased activity of these drugs. (7.2) For patient counseling information and FDA-approved patient labeling, see page 17. . Revised: September 2019 Full Prescribing Information: Table of Contents * 1. Indications and usage 2. Dosage and Administration 2.1 Recommended Dosage 2.2 Dose adjustment 3. Dosage forms and contents 4 contraindications 5. Warnings and Precautions 5.1 Ischemic cardiovascular events 5.2 Fracture 5.3 Falls 5.4 Seizures 5.5 Embryo-fetal toxicity 6. Adverse Reactions 6.1 Clinical trial experience 7. Drug Interactions 7.1 Effects of other drugs on ERLEADA 7.2 Effect of ERLEADA on other drugs 8. Use in Specific Populations 8.1 Pregnancy 8.2 Breastfeeding 8.3 Women and men of reproductive potential 8.4 Pediatric Use 8.5 Elderly Use 10 Overdose 11 properties 12 Clinical Pharmacology 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 Non-clinical toxicity 13.1 Carcinogenesis, Mutagenesis, and Reproductive Harm 14 Clinical Trials 16. Supply / Storage / Handling Methods 17 Patient Counseling Information * Chapters or subchapters omitted from the full prescribing information are not listed.

[0281] Full prescribing information 1. Indications and usage ERLEADA is ●Metastatic castration-sensitive prostate cancer (mCSPC) Indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) do.

[0282] 2. Dosage and Administration 2.1 Recommended Dosage The recommended dose of ERLEADA is 240 mg (four 60 mg tablets) taken orally once daily. Swallow the tablet whole. ERLEADA can be taken with or without food. It may also be used.

[0283] Patients also receive gonadotropin-releasing hormone (GnRH) analogs concomitantly. or have had both testicles removed.

[0284] 2.2 Dose adjustment If a patient experiences Grade 3 or higher toxicity or intolerable side effects, symptoms should be Grade 1 or lower. or withhold treatment until improvement to the original grade or below, then, if permitted, continue treatment with the same Resume at the full or reduced dose (180 mg or 120 mg).

[0285] 3. Dosage forms and contents Tablets (60 mg): Slightly yellowish to gray-green, oval, film-coated A lock with "AR60" debossed on one side.

[0286] 4 contraindications none.

[0287] 5. Warnings and Precautions 5.1 Ischemic cardiovascular events Ischemic cardiovascular events, including fatal events, were reported in patients taking ERLEADA. Monitor for signs and symptoms of ischemic heart disease. Hypertension, diabetes, or dyslipidemia. Optimize management of cardiovascular risk factors, including cardiovascular disease. For grade 3 and 4 events Consider discontinuing ERLEADA.

[0288] In a randomized trial (SPARTAN) of patients with nmCRPC, Vents occurred in 4% of patients treated with ERLEADA and 3% of patients treated with placebo. In a randomized trial of patients with mCSPC (TITAN), The incidence of ERLEADA-treated patients was 4% and 2% of placebo-treated patients. Across the SPARTAN and TITAN trials, 6 patients treated with ERLEADA 1 patient (0.5%) and 2 placebo-treated patients (0.2%) developed ischemic cardiovascular events. Death from ventricular failure. Unstable angina, myocardial infarction, or congestive heart failure within 6 months of randomization. Patients with all current evidence were excluded from the SPARTAN and TITAN trials. It was.

[0289] 5.2 Fracture Fractures have occurred in patients taking ERLEADA. Patients were assessed for fracture risk. Monitor and manage patients at risk for fracture according to established treatment guidelines; Consider bone-targeted agents.

[0290] In a randomized trial of patients with non-metastatic castration-resistant prostate cancer (SPARTAN), E Fractures occurred in 12% of patients treated with RLEADA and 7% of patients treated with placebo Grade 3-4 fractures occurred in 3% of patients treated with ERLEADA and 1% of patients treated with placebo. It occurred in 1% of treated patients. The mean time to fracture was For patients treated with IFN-γ, the mean time to maturity was 314 days (range: 20-953 days). Assessment of osteoporosis severity and treatment of osteoporosis with bone-targeted drugs were not performed in the SPARTAN trial. It was.

[0291] In a randomized trial of patients with metastatic castration-sensitive prostate cancer (TITAN), ER Fractures occurred in 9% of patients treated with LEADA and 6% of patients treated with placebo. Grade 3-4 fractures occurred in both groups at a similar rate of 2%. The median was 56 days (range: 2-111 days) for patients treated with ERLEADA. Routine bone mineral density assessment and treatment of osteoporosis with bone-targeted drugs were not performed in the TITAN trial. This was not carried out.

[0292] 5.3 Falls Falls occurred with increased frequency in elderly patients taking ERLEADA [specific See Use in Other Populations (8.5). Assess the patient for fall risk. thing.

[0293] In a randomized trial (SPARTAN), falls occurred in ERLEADA-treated patients. occurred in 16% of patients treated with placebo compared with 9% of patients treated with placebo. The falls were not associated with loss of consciousness or seizures.

[0294] 5.4 Seizures Seizures have occurred in patients taking ERLEADA. Patients who develop seizures during treatment If antiepileptic drugs are used, ERLEADA should be discontinued permanently. It is not known if ERLEADA prevents seizures. risk of sudden loss of consciousness causing harm to self or others Advise patients of the risks of participating in the activity.

[0295] In two randomized trials (SPARTAN and TITAN), patients treated with ERLEADA Five patients (0.4%) treated with steroids and one patient (0.1%) treated with placebo experienced seizures. Seizures occurred 159 to 650 days after the start of ERLEADA. Patients with a predisposition to seizures or taking drugs known to lower the seizure threshold or induce seizures Clinical experience with rechallenge with ERLEADA in patients who have experienced a seizure There is no.

[0296] 5.5 Embryo-fetal toxicity The safety and effectiveness of ERLEADA have not been established in women. Based on the data, ERLEADA may cause fetal harm when administered to a pregnant woman. May cause pregnancy loss [see Clinical Pharmacology (12.1)]. Men with female partners who had ERLEADA were randomly assigned to receive ERLEADA for 3 months during treatment and after the last dose. Advising on effective contraceptive use for months ["Use in certain populations"] See "Use" (8.1, 8.3).

[0297] 6. Adverse Reactions The following are discussed in more detail in other sections of the accompanying document: Ischemic cardiovascular events [see Warnings and Precautions (5.1)]. • Fractures [see Warnings and Precautions (5.2)]. • Falling [See Warnings and Precautions (5.3)]. • Seizures [see Warnings and Precautions (5.4)].

[0298] 6.1 Clinical trial experience The clinical trials observed in drug clinical trials are conducted under widely varying conditions. Adverse reaction rates cannot be directly compared with rates in clinical trials of other drugs and are not based on observed may not reflect the actual rates.

[0299] ERLEADA Treatment from Randomized Placebo-Controlled Clinical Trials (TITAN and SPARTAN) The most common adverse reactions (≥ 2% more frequent than placebo) occurred in treated patients. 10%) experienced fatigue, arrhythmia, rash, loss of appetite, falls, weight loss, high blood pressure, hot flashes, and diarrhea. , and fractures.

[0300] Metastatic castration-sensitive prostate cancer (mCSPC) TITAN, a randomized (1:1), double-blind, placebo-controlled, multicenter clinical trial, Patients with mCSPC were enrolled in this study. In this study, patients received a daily dose of 240 mg All patients in the TITAN trial received either ERLEADA or a placebo. received concomitant gonadotropin-releasing hormone (GnRH) analogs, or previously had bilateral semen resection. The median duration of exposure was 20 months ( range: 0-34 months) and 18 months (range: 0.1-3 months) in patients receiving placebo. (4 months).

[0301] Ten patients (2%) treated with ERLEADA died from adverse reactions. The incidence of ischemic cardiovascular events was 3 (n=3), acute kidney injury was 2 (n=2), and cardiac arrest was 1 (n=1). Sudden cardiac death (n=1), respiratory failure (n=1), cerebrovascular accident (n=1), and colonic ulcer perforation ERLEADA was discontinued due to adverse reactions in 8% of patients. Rash was the most common symptom (2%), leading to interruption or dose reduction of ERLEADA. Adverse reactions occurred in 23% of patients, the most common (>1%) being rash and fatigue. Severe adverse reactions occurred in 20% of ERLEADA-treated patients and 10% of placebo-treated patients. This occurred in 20% of patients who took

[0302] Table 1 shows the TITAN-related adverse events that occurred with an absolute increase of ≥2% in frequency compared with placebo. Table 2 shows adverse reactions occurring in ≥10% of patients in the ERLEADA group. 5% and more frequently in the ERLEADA group compared with placebo (> 5%) and shows abnormal test results.

[0303] [Table 10] 1 Symptoms include fatigue and asthenia. 2 Skin rash, maculopapular rash, generalized rash, urticaria, pruritic rash, macular rash, conjunctivitis, polymorphous erythema, papular eruption, skin exfoliation, genital eruption, erythematous eruption, stomatitis, drug eruption, oral ulcer, These include pustular eruptions, blisters, papules, pemphigoid, skin erosions, dermatitis, and vesicular eruptions. do. 3 According to the Common Terminology Criteria for Adverse Reactions (CTCAE), the most severe of these events was is grade 3.

[0304] This occurs in 2% but less than 10% of patients treated with ERLEADA, which is interesting. Further adverse reactions included diarrhea (9% vs. 6% with placebo), muscle cramps (3% vs. 2% with placebo), and %), dysgeusia (3% vs. 1% with placebo), and hypothyroidism (4% vs. 1% with placebo) 1%) was included.

[0305] [Table 11] 1 Does not reflect fasting values

[0306] Non-metastatic castration-resistant prostate cancer (nmCRPC) SPARTAN, a randomized (2:1), double-blind, placebo-controlled, multicenter clinical trial Patients with nmCRPC were enrolled in this study. Patients received either a 200mg dose of ERLEADA or a placebo. All patients receiving concomitant gonadotropin-releasing hormone (GnRH) analogues or both Patients receiving ERLEADA underwent a unilateral orchiectomy. The median duration of exposure was 1 6.9 months (range: 0.1-42 months) and 11.2 months in patients receiving placebo (range: 0.1 to 37 months).

[0307] Eight patients (1%) treated with ERLEADA died from adverse reactions. , infection (n=4), myocardial infarction (n=3), and cerebral hemorrhage (n=1). One patient (0.3%) died from an adverse reaction of cardiopulmonary arrest (n=1), and one patient (0.3%) died from an ERLEA. DA was discontinued in 11% of patients due to adverse reactions, the most common being rash ( Adverse reactions leading to dose interruption or reduction of ERLEADA occurred in 33% of patients. The most common side effects were rash, diarrhea, fatigue, nausea, vomiting, high blood pressure, and hematuria. Severe adverse reactions occurred in 25% of patients treated with ERLEADA and 25% of patients treated with placebo. The most common severe adverse reaction (>2%) was E Fractures occurred in the RLEADA group (3%) and urinary retention in the placebo group (4%) .

[0308] Table 3 shows the absolute incidence of adverse events in SPARTAN with a frequency of ≥2% compared with placebo. Table 4 shows adverse reactions occurring in ≥10% of patients in the ERLEADA group. % and was more frequent (>5%) in the ERLEADA group compared with placebo The abnormalities in the test results are shown.

[0309] [Table 12] 1 Symptoms include fatigue and asthenia. 2 Rash, maculopapular rash, generalized rash, urticaria, pruritic rash, macular rash, conjunctivitis, polymorphous erythema, papular eruption, skin exfoliation, genital eruption, erythematous eruption, stomatitis, drug eruption, oral ulcer, These include pustular eruptions, blisters, papules, pemphigoid, skin erosions, dermatitis, and vesicular eruptions. do. 3 Rib fractures, lumbar fractures, spinal compression fractures, vertebral fractures, leg fractures, hip fractures, humerus fractures, Thoracic spine fractures, upper limb fractures, sacrum fractures, hand fractures, pubic bone fractures, acetabular fractures, ankle fractures, compression fractures , costochondral fractures, facial bone fractures, lower limb fractures, osteoporotic fractures, hand fractures, avulsion fractures, fibula fractures Fractures of the tailbone, pelvis, radius, sternum, stress fractures, traumatic fractures, cervical spine fractures, femoral fractures These include fractures of the femoral neck and tibia. 4 According to the Common Terminology Criteria for Adverse Reactions (CTCAE), the most severe of these events was is grade 3 5 Appetite disorders, including loss of appetite, early satiety, and anorexia 6 Peripheral edema, generalized edema, edema, genital edema, penile edema, peripheral swelling, scrotal edema, These include edema, swelling, and localized edema.

[0310] Further clinically significant adverse events occurred in 2% or more of patients treated with ERLEADA Adverse reactions included hypothyroidism (8.1% vs. 2% for placebo), pruritus (6.2% vs. 2% for placebo), and These included heart failure (2.2%, vs. 1% for placebo) and stroke (2.2%, vs. 1% for placebo).

[0311] [Table 13] 1 Does not reflect fasting values

[0312] rash Combined data from two randomized, placebo-controlled clinical trials showed no significant association with ERLEADA. The rash was most commonly described as a macular or maculopapular rash. reported in 26% of patients treated with ERLEADA compared with 10% treated with placebo Grade 3 rash (>100% of body surface area [BSA]) was reported in 8% of treated patients. 30%) compared with placebo (0.5%) compared with ERLEADA treatment (6%). %) was reported.

[0313] The onset of rash occurred after a median of 83 days of ERLEADA treatment. Rash occurred in 78 patients. In % of patients, the rash resolved within a median of 78 days after onset. In patients receiving antihistamines, topical corticosteroids, and systemic corticosteroids Dose reductions occurred in 14% of patients and dose interruptions occurred in 28% of patients. Of patients who discontinued treatment, 59% experienced a recurrence of rash upon reintroduction of ERLEADA. did.

[0314] hypothyroidism Combined data from two randomized, placebo-controlled clinical trials showed that hypothyroidism was associated with a 4 Based on monthly thyroid-stimulating hormone (TSH) assessment reported in 8% of patients treated with ERLEADA and 2% of patients treated with placebo. Increases in TSH were observed in 25% of patients treated with ERLEADA and 25% of patients treated with placebo. It occurred in 7% of patients who underwent steroid therapy. The median onset was at the first scheduled evaluation. There were no grade 3 or 4 adverse reactions. Thyroid replacement therapy was administered by ERLEADA. Thyroid replacement therapy was initiated in 5% of patients treated with thyroidectomy if clinically indicated. Initiation or dose adjustment may be necessary [see Drug Interactions (7.2)].

[0315] 7. Drug Interactions 7.1 Effects of other drugs on ERLEADA Strong CYP2C8 or CYP3A4 inhibitors Coadministration of strong CYP2C8 or CYP3A4 inhibitors may result in the release of the active moiety (unbound apatite). Steady-state exposure of apalutamide (total of N-desmethylapalutamide + potency-adjusted unbound N-desmethylapalutamide) However, no initial dose adjustment is necessary and the ER should be increased based on tolerability. Reduce LEADA dose [see Dosage and Administration (2.2)]. Mild or moderate inhibitors of CYP3A4 are not expected to affect the exposure of apalutamide. It is not expected.

[0316] 7.2 Effect of ERLEADA on other drugs Substrates of CYP3A4, CYP2C9, CYP2C19, and UGTs ERLEADA is a potent inducer of CYP3A4 and CYP2C19 in humans. It is a weak inducer of CYP2C9. Concomitant use with drugs primarily metabolized by CYP2C19 and CYP2C9 may increase the risk of side effects to these drugs. Alternatives to these agents are recommended where possible, or if the agent is The purpose of this study is to evaluate the decrease in activity if the treatment is continued. It is a substrate for UDP-glucuronosyl transferase (UGT). Coadministration of drugs with the same substrate for LIGT as ERLEADA may result in reduced exposure. If administered immediately, caution should be exercised and evaluation for loss of activity should be performed [see Clinical Pharmacology (12.3)]. I want to be illuminated.

[0317] Substrate of P-gp, BCRP, or OATP1B1 Apalutamide inhibits P-glycoprotein (P-gp), a breast cancer resistance protein. (breast cancer resistance protein, BCRP), and organic anion transporting polypeptide Weak inducer of 1B1 (organic anion transporting polypeptide 1B1, OATPIB1) At steady state, apalutamide has been shown to be Plasma exposure to statin (a P-gp substrate) and rosuvastatin (a BCRP / OATPIB1 substrate) The ERLEAD of drugs that are substrates of P-gp, BCRP, or OATP1B1 was reduced. The combination of P-gp, BCRP, or O may result in lower exposure of these agents. Caution should be exercised when coadministering ATPIB1 substrates with ERLEADA, and if the drug is continued If so, evaluate for loss of activity [see Clinical Pharmacology (12.3)].

[0318] 8. Use in Specific Populations 8.1 Pregnancy Risk Overview The safety and effectiveness of ERLEADA have not been established in women. Based on the data, ERLEADA may cause harm to the fetus and result in pregnancy loss. [See Clinical Pharmacology (12.1)]. There are no human data available. ERLEADA is indicated for use in women. Therefore, no embryo-fetal developmental toxicity studies in animals have been conducted with apalutamide.

[0319] 8.2 Breastfeeding Risk Overview The safety and effectiveness of ERLEADA have not been established in women. the presence of apalutamide or its metabolites in breast-fed infants; There are no data on the effect on breast milk production or breastfeeding.

[0320] 8.3 Women and men of reproductive potential contraception male Based on the mechanism of action and findings from animal reproduction studies, female partners of reproductive potential Effective during treatment and for 3 months after the most recent dose of ERLEADA in male patients with Advise on the use of contraception [see Use in Specific Populations (8.1)]. sea ​​bream].

[0321] infertility male Based on animal studies, ERLEADA impairs fertility in reproductive men Possible [see Nonclinical Toxicity (13.1)].

[0322] 8.4 Pediatric Use The safety and effectiveness of ERLEADA in pediatric patients has not been established.

[0323] 8.5 Elderly Use Of the 1,327 patients who took ERLEADA in clinical trials, 19% of patients Most patients were under 65 years old, 41% were between 65 and 74 years old, and 40% were over 75 years old. .

[0324] No overall difference in efficacy was observed between older and younger patients.

[0325] Among patients treated with ERLEADA (n=1073), grade 3-4 adverse reactions 39% of patients younger than 65 years, 41% of patients aged 65-74 years, and 41% of patients aged 75 years or older occurred in 49% of patients taking ERLEADA in conjunction with androgen deprivation therapy. Falls due to stroke are more common in older adults, occurring in 8% of patients under 65, 10% of patients aged 65-74, and It occurred in 19% of patients aged 75 years or older.

[0326] 10 Overdose There are no known specific countermeasures for apalutamide overdose. In the event of an overdose, If this occurs, ERLEADA should be discontinued and overall support provided until clinical toxicity is attenuated or resolved. To take measures.

[0327] 11 properties Apalutamide, the active ingredient in ERLEADA, is an androgen receptor inhibitor. The chemical name is (4-[7-(6-cyano-5-trifluoromethylpyridine-3-yl]pyridin-3-yl) (yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl] Apalutamide is a white to slightly pigmented Apalutamide is a yellow powder. It is practically insoluble in aqueous media over a wide range of pH values. It is sex.

[0328] The molecular weight is 477.44 and the molecular formula is C 21 H 15 The structural formula is F4N5O2S. It is as follows:

[0329] [ka]

[0330] ERLEADA (apalutamide) is a 60 mg oral dose of apalutamide. The inactive ingredients in the core tablet are colloidal Silica anhydrous, croscarmellose sodium, hydroxypropyl methylcellulose Acetate succinate, magnesium stearate, microcrystalline cellulose, and silicified microcrystalline cellulose It is crystalline cellulose.

[0331] The tablets contain the following excipients: black iron oxide, yellow iron oxide, polyethylene glycol Commercially available film coatings containing cellulose acetate, polyvinyl alcohol, talc, and titanium dioxide. It is finished with a rubber finish.

[0332] 12 Clinical Pharmacology 12.1 Mechanism of Action Apalutamide binds directly to the ligand-binding domain of the androgen receptor (AR) Apalutamide is an AR inhibitor. It inhibits the nuclear translocation of AR, inhibits DNA binding, and inhibits AR The main metabolite, N-desmethylapalutamide, inhibits transcription mediated by AR. and is a weak inhibitor of apalutamide in an in vitro transcriptional reporter assay. Apalutamide treatment reduced tumor cell proliferation and inhibited the proliferation of prostate cancer tumors. Increased apoptosis leading to reduced tumor volume in mouse xenograft models.

[0333] 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of 240 mg apalutamide once daily on the QTc interval was evaluated in 45 patients with CRPC. The study was conducted in an open-label, uncontrolled, multicenter, single-arm, thorough QT study in patients with The maximum mean QTcF change from 12.4 ms (two-sided 90% upper limit CI: 16.0 ms) Exposure-QT analysis revealed a concentration-dependent change in QTcF for apalutamide and its active metabolites. This suggests a significant increase.

[0334] 12.3 Pharmacokinetics Pharmacokinetic parameters of apalutamide are expressed as mean [standard deviation] unless otherwise specified. The C of apalutamide is shown as the mean mean deviation (SD). max and area under the concentration curve (AUC) is 30 to 480 mg (0.125 to 2 times the recommended dose) administered once daily. After 4 weeks of administration of the recommended dose, apalutamide reached a steady state and The average accumulation rate was approximately 5-fold. max is 6.0mcg / mL (1.7), and the AUC was 100 mcg h / mL (32). The diurnal variation in plasma concentrations of amide was small, with a mean peak-to-trough ratio of 1.63. In this study, an increase in apparent clearance (CL / F) was observed, and apalutamide itself This is likely due to the induction of metabolic effects of Apalutamide exposure is dose-proportional, so the autoinduction effect is greatest at the recommended dose. It is highly likely that it was achieved.

[0335] At steady state after recommended dosing, the C of the major active metabolite, N-desmethylapalutamide max was 5.9 mcg / mL (1.0), and the AUC was 124 mcg h / mL (23 N-desmethylapalutamide had a mean peak-to-valley ratio of 1.27. It was characterized by a flat concentration time profile under normal conditions. The mean AUC metabolite / parent drug ratio for N-desmethylapultamide was 1.3. Systemic exposure, relative potency, and pharmacokinetic properties indicate that N-desmethylapalutamide , likely contributing to the clinical activity of apalutamide.

[0336] absorption The mean oral absolute bioavailability was approximately 100%. Peak plasma concentrations (maximum) were reached The median time to recovery was 2 hours (range: 1-5 hours).

[0337] Food effects under fasting conditions and on a high-fat diet (approximately 500-600 fat calories, 250 carbohydrates) Apalutamide with 100 calories and 150 protein calories (150 calories) administered to healthy subjects In administration, C max No clinically relevant changes in AUC and t max reach The median time to urination was delayed by approximately 2 hours with food.

[0338] distribution The mean apparent volume of distribution of apalutamide at steady state was approximately 276 L.

[0339] Apalutamide achieved 96% and N-desmethylapalutamide achieved 95% in a concentration-dependent manner. It was highly bound to plasma proteins.

[0340] Disappearance The CL / F of apalutamide was 1.3 L / h after a single dose and 1.4 L / h after a steady-state administration of once-daily The blood pressure increased to 2.0 L / h in this state, which may be due to CYP3A4 autoinduction. The mean effective half-life for apalutamide in patients was approximately 3 days at steady state. there were.

[0341] metabolic effect Metabolism is the major route of elimination of apalutamide. Apalutamide is primarily eliminated by C It is metabolized by YP2CS and CYP3A4 to produce the active metabolite N-desmethylaspartate. The role of CYP2CS and CYP3A4 in the metabolism of apalutamide The doses are estimated to be 58% and 13% after a single dose, but 40% at steady state, respectively. % and 37%.

[0342] After a single oral dose of 240 mg radiolabeled apalutamide, the total AUC was apalutamide accounted for 45% and N-desmethylapultamide accounted for 44%.

[0343] excretion After a single oral dose of radiolabeled apalutamide, 65% of the dose was excreted in urine for up to 70 days. Recovered (1.2% of the dose as unchanged apalutamide and 2.7% as N-desmethicone) as ripartamide), and 24% was recovered in the feces (1.5% of the dose was unchanged). as palutamide, and 2% as N-desmethyl palutamide).

[0344] Specific populations There are no clinically significant differences in the pharmacokinetics of apalutamide or N-desmethylapalutamide. , age (18-94 years), race (black, non-Japanese Asian, Japanese), mild to moderate (eGF R 30~89mL / min 1.73m 2 According to the Modification of Diet in Renal Disease (MDRD) formula, Renal impairment (presumed to be caused by the kidney) or mild (Child-Pugh A) to moderate (Child-Pugh B) Pugh B) liver damage was not observed.

[0345] Severe renal impairment or end-stage renal disease (eGFR ≤ 29 mL / min / 1.73 m 2 , M.D.R.D. ) or severe hepatic impairment (Child-Pugh C) on the pharmacokinetics of apalutamide is unknown.

[0346] Drug interactions Effects of other drugs on ERLEADA Strong CYP2C8 inhibitor ERLEADA as a single 240 mg dose with gemfibrozil (a potent CYP2C8 C of apalutamide after coadministration with max fell 21%, while AU C increased by 68%. Gemfibrozil significantly increased the C of apalutamide at steady state. max 32% Apalutamide is predicted to increase the AUC by 44%. The predicted steady-state (total unbound N-desmethylapalutamide, adjusted for potency) C in attitude max increased by 19% and AUC increased by 23%.

[0347] Strong CYP3A4 inhibitor ERLEADA as a single 240 mg dose with itraconazole (a potent CYP3A4 C of apalutamide after coadministration with max decreased by 22%, while AUC Ketoconazole (a strong CYP3A4 inhibitor) was administered as a single dose of Increased the AUC of luteamide by 24%, but max is not expected to affect keto Conazole significantly increased the C of apalutamide at steady state. max increased by 38% and AUC by 51% The active moiety is predicted to be max increased by 23% and AUC increased by 28%.

[0348] CYP3A4 / CYP2C8 inducers Rifampin (a strong CYP3A4 inducer and a moderate CYP2C8 inducer) The steady-state C of apalutamide max reduced by 25% and AUC by 34% The active moiety is predicted to decrease the steady-state Cmax decreased by 15% The AUC decreased by 19%.

[0349] Acid reducers Apalutamide is not ionizable under relevant physiological pH conditions and is therefore an acid-lowering agent. (e.g., proton pump inhibitors, H2 receptor antagonists, antacids) may affect the solubility of apalutamide. and is not expected to affect bioavailability.

[0350] Drugs that affect transporters In vitro, apalutamide and N-desmethylapalutamide act as a substrate for P-gp. It is a substrate of BCRP, OATPIB1, and OATP1B3, but is not a substrate of BCRP, OATPIB1, or OATP1B3. Since apalutamide is subsequently completely absorbed, P-gp does not limit the absorption of apalutamide. Therefore, inhibition or induction of P-gp may affect the bioavailability of apalutamide. It is not expected to be.

[0351] ERLEADA's effects on other drugs CYP substrate In vitro studies have shown that apalutamide and N-desmethylapalutamide inhibit CYP It is a moderate to strong inducer of CYP3A4 and CYP2B6, and is a potent inducer of CYP2B6 and CYP2 It is a moderate inhibitor of C8 and a weak inhibitor of CYP2C9, CYP2C19, and CYP3A4. Apalutamide and N-desmethylapalutamide were shown to be therapeutic inhibitors. It has no effect on CYP1A2 and CYP2D6 at the same concentration.

[0352] Coadministration of ERLEADA with a single oral dose of a sensitive CYP substrate results in a significant reduction in the risk of CYP-related cytotoxicity compared with midazolam (C A 92% decrease in the AUC of omeprazole (a CYP2C19 substrate) and An 85% decrease in UC and a 46% decrease in AUC of S-warfarin (a CYP2C9 substrate) ERLEADA resulted in a clinically significant reduction in exposure to CYP2CS substrates. Didn't cause any change.

[0353] Substrate of P-gp, BCRP, and OATP1B1 Co-administration of ERLEADA with a single oral dose of a transporter substrate is A 30% decrease in the AUC of phenazine (a P-gp substrate) and rosuvastatin (BCRP / O ATPIB1 substrate), but C max It has no effect on It was.

[0354] UGT substrate Apalutamide can induce UGT. ERLEADA is a drug that is a substrate of UGT. Coadministration of these drugs may result in decreased exposure to these agents.

[0355] Substrates of OCT2, OAT1, OAT3, and MATES In vitro, apalutamide and N-desmethylapalutamide react with organic cations Organic cation transporter 2 (OCT2), organic anion transporter organic anion transporter 3 (OAT3), and multidrug toxin extrusion inhibits tidrug and toxin extrusion (MATE) and inhibits organic anion transporter 1 Apalutamide does not induce clinically significant changes in exposure to OAT3 substrates. It is not predicted to occur.

[0356] GnRH analogues Taking leuprolide acetate (a GnRH analog) co-administered with apalutamide In subjects with mCSPC, PK data demonstrated that apalutamide significantly improved the steady-state activity of leuprolide. showed no apparent effect on dew.

[0357] 13 Non-clinical toxicity 13.1 Carcinogenesis, Mutagenesis, and Reproductive Harm No long-term animal studies have been conducted to evaluate the carcinogenic potential of apalutamide. does not induce mutations in the microbial reverse mutation (Ames) test and chromosome aberration assay, or in vivo rat bone marrow micronucleus assay or in There was no genotoxicity in either the in vivo rat comet assay.

[0358] In repeated-dose toxicity studies in male rats (up to 26 weeks) and dogs (up to 39 weeks), This may include atrophy of the prostate and seminal vesicles, azoospermia / oligozoospermia, tubular cytosis of the interstitial cells of the reproductive system, Degeneration and / or hyperplasia, or hypertrophy, occurred in rats at ≥ 25 mg / kg / day (AUC in dogs (1.4 times the human exposure based on AUC This was observed at a dose of 0.9 times the human exposure.

[0359] In fertility tests in male rats, decreased sperm concentration and sperm motility were observed. Sperm morphological abnormalities, reduced mating and fertility (when mated with untreated females), along with accessory sex glands and epididymis weight loss was observed after 4 weeks of treatment with ≥ 25 mg / kg / day (based on AUC in humans). The results were observed after 4 weeks of 150 mg / kg / day (based on AUC) After administration of 5.7 times the exposure to IFN-γ, increased pre- and / or post-transplant mortality was observed. A reduction in the number of fetuses born was observed. The effect on male rats was not observed after the most recent administration of apalutamide. The patient was able to recover after 8 weeks.

[0360] 14 Clinical Trials The efficacy and safety of ERLEADA were established in two randomized, placebo-controlled clinical trials did.

[0361] TITAN (NCT02489318): Metastatic castration-sensitive prostate cancer (mCSPC) TITAN is a randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of mCSPC. 1052 patients were randomized (1:1) to receive E1400 orally at a dose of 240 mg once daily. They received either RLEADA (N=525) or a placebo (N=527) once daily. All patients in the TITAN trial had received GnRH analogues or had previously undergone bilateral cerebral infarction. The lesion was removed. Patients were randomly assigned based on their Gleason score at diagnosis, prior docetaxel use, and Stratified by world region. Patients with both high-volume and low-volume mCSPC were eligible for the study. High-volume disease was defined as visceral disease with one bone lesion or four or more bone lesions. The presence of metastases involving four or more bone lesions, at least one of which is spinal It must be in the bony structure beyond the column and pelvic bone.

[0362] The following patient demographic and baseline disease characteristics were balanced between treatment groups: The median age was 68 years (range 43-94 years), and 23% of patients were 75 years or older. The racial distribution was 68% White, 22% Asian, and 2% Black, with 63% 16% of patients had high-volume disease and 37% had low-volume disease. The majority of patients had undergone surgery, radiation therapy, or both. 68% of patients had a steroid score (67%). 68% of patients were treated with antiandrogens (bicalutamide, All patients except one in the placebo group had received prior treatment with fluthamide or nilutamide. All patients were assessed according to the Eastern Cooperative Oncology Group performance status at study entry. The ECOG performance status score was 0 or 1.

[0363] The primary efficacy outcome measures of the study were overall survival (OS) and radiological Progression-free survival (PFS) was measured by radiological imaging. Based on physician assessment and randomized to radiological imaging diagnosis of disease progression or death. Radiographic disease progression was defined as the time from onset of prostate cancer. Two or more new bone lesions on bone scan with Working Group 2 criteria and / or was defined by exacerbation of soft tissue disease.

[0364] Statistically significant improvements in OS and rPFS were observed compared with patients randomized to receive placebo OS results were shown in patients randomized to receive ERLEADA compared with Based on a pre-specified interim efficacy analysis, the efficacy results of TITAN are shown in Table 5 and Figure 1. The results are summarized in Figure 2.

[0365] [Table 14] a The interim analysis is based on 50% of the number of events planned for the final analysis. α = 0.01. b Hazard ratios are derived from stratified proportional hazards models, and hazard ratios less than 1 are associated with E RLEADA has the advantage. cp values ​​are from the log-rank test stratified by Gleason score at diagnosis (≤7 vs. >7). The data were derived from the following criteria: location (NA / EU vs. other countries) and prior docetaxel use (yes vs. no). do. d NE = Not calculated

[0366] Consistent improvements in rPFS were observed across the following patient subgroups: volume (high vs. low), prior docetaxel use (yes vs. no), and grief status at diagnosis. score (≤7 vs. >7).

[0367] Consistent improvements in OS were observed across the following patient subgroups: disease volume (high vs. low) and Gleason score at diagnosis (≤7 vs. >7).

[0368] Treatment with ERLEADA resulted in a statistically significant delay in the initiation of cytotoxic chemotherapy ( HR=0.39,95%CI=0.27,0.56;p<0.0001).

[0369] Figure 1: Kaplan-Meier plot of overall survival (OS); mCSP in the intention-to-treat analysis Group C (TITAN) TIFF2024161428000024.tif89128

[0370] [Table 15]

[0371] Figure 2: Kaplan-Meier plot of progression-free survival (rPFS) by radiological imaging. mCSPC population for the intent-to-treat analysis (TITAN) TIFF2024161428000026.tif89128

[0372] [Table 16]

[0373] SPARTAN (NCT01946204): Nonmetastatic castration-resistant prostate cancer (nmCR) PC) SPARTAN is a multicenter, double-blind, randomized (2:1), placebo-controlled clinical trial. 1207 patients with nmCRPC were randomized (2:1) to receive 240 mg once daily. Patients received either ERLEADA (N=806) or placebo (N=401) orally once daily. All patients in the SPARTAN trial received concomitant gonadotropin-releasing Patients received prostate-specific gonadotropin (GnRH) analogs or underwent bilateral orchiectomy. Antigen (PSA) doubling time (PSADT), Patients were stratified by use of bone-sparing agents and locoregional disease. Patients had a PSADT ≤ 1 0 months and confirmation of non-metastatic disease by blinded independent central review (BICR). PSA results were blinded and were not used to discontinue treatment. Patients were diagnosed with radiological disease progression confirmed by BICR, localized progression only, and Treatment was discontinued due to illness, initiation of new therapy, unacceptable toxicity, or desire to discontinue.

[0374] The following patient demographic and baseline disease characteristics were balanced between treatment groups: The median age was 74 years (range 48-97 years), and 26% of patients were 80 years or older. The racial distribution was 66% White, 12% Asian, and 6% Black. In this treatment group, 77 percent (77%) of patients had previous prostate surgery or radiation therapy. Most patients had a Gleason score of 7 or higher (78%). Fifteen percent of patients had pelvic lymph nodes measuring 2 cm at study entry. 73% of patients Prior antiandrogen therapy was administered, with 69% of patients receiving bicalutamide. Ten percent of patients were taking flutamide. All patients were from the Eastern United States at study entry. Coastal Cancer Clinical Trials Group Performance Status (ECOG PS) performance status The score was 0 or 1. Patients who discontinued study treatment (placebo N=279 and ER N=279) Among LEADA patients (N=314), those treated with placebo received subsequent therapy The rate (80%) was higher than in patients treated with ERLEADA (56%). Locoregional progression occurred in 2% of patients overall.

[0375] The primary efficacy outcome measure of the study was metastasis-free survival (MFS), which was confirmed by BICR. The first 24-hour follow-up was defined as the time from randomization to the time of first evidence of distant metastasis. Evidence may include new lesions or soft tissue lesions, or intestinal lesions, whichever occurs first. This was defined as lymph node enlargement above the bony bifurcation or death from any cause. The endpoints were time to metastasis (TTM) and progression-free survival (PFS). Also included were locoregional progression, time to progression, and overall survival (OS). .

[0376] Patients randomized to receive ERLEADA were significantly more likely to receive placebo than those randomized to receive placebo. A statistically significant improvement in MFS was observed in patients with PSADT (≤6 months or >6 months), prior bone-sparing agent use (yes or no), and locoregional disease (N0 Consistent results were observed across patient subgroups, including N1 or N2. Outcomes were driven by statistically significant improvements in TTM, PFS, and time to disease progression. Overall survival (OS) data were not mature at the time of the final MFS analysis. (24% of the number of events required). The PFS efficacy results are summarized in Figure 3 and Table 6.

[0377] Figure 3: Kaplan-Meier metastasis-free survival (MSF) in SPARTAN (nmCRPC) MFS) curve TIFF2024161428000028.tif70128

[0378] [Table 17]

[0379] [Table 18] 1 All analyses were performed by PSA doubling time, use of bone-sparing agents, and locoregional disease status. The data was stratified. NE = Not calculated

[0380] 16. Supply / Storage / Handling Methods ERLEADA (apalutamide) 60 mg film-coated tablets are slightly yellowish. The tablets are light to gray-green in color, oval in shape, and have "AR60" debossed on one side. ERLEADA 60 mg tablets are available in bottles of 120 tablets. Contains silica gel desiccant. NDC Number 59676-600-12

[0381] Storage and Handling Store between 20°C and 25°C (68°F and 77°F). Store between 15°C and 30°C (59°F and 86°F). Temporary fluctuations in the range of °F (USP "Controlled Room Temperature") are acceptable. See "Temperature" for more information.

[0382] Store in original packaging. Do not discard desiccant. Protect from light and moisture.

[0383] 17 Patient Counseling Information Advise patients to read the FDA-approved package insert (Patient Information).

[0384] Ischemic cardiovascular events Inform patients that ERLEADA is associated with ischemic cardiovascular events If any symptoms suggestive of a cardiovascular event occur, seek medical advice. Advise patients [see Warnings and Precautions (5.1)].

[0385] Falls and fractures Inform patients that ERLEADA is associated with an increased incidence of falls and fractures [See Warnings and Precautions (5.2, 5.3)].

[0386] Seizures Inform patients that ERLEADA is associated with an increased risk of seizures. Discuss conditions that may predispose to seizures and medications that may lower the seizure threshold, and Risk participating in any activity where loss could cause serious harm to self or others Advise patients to contact their healthcare provider if they are experiencing seizures. Inform patients [see Warnings and Precautions (5.4)]

[0387] rash Inform patients that ERLEADA is associated with a rash and if a rash occurs, Inform patients about the adverse reactions they should notify their healthcare provider if See 1).

[0388] Dosage and Administration For patients receiving concomitant therapy with gonadotropin-releasing hormone (GnRH) analogues, Informing you of the need to maintain treatment with RLEADA during the course of treatment. • Instruct the patient to take their dose at the same time each day (once daily). ERLEADA may be taken with or without food. Take each tablet in its entirety. You have to swallow it. If a daily dose of ERLEADA is missed, advise the patient to take the same dose as their usual dose. Take the missed dose as soon as possible on the first day of each month, and resume your regular schedule the next day. Do not have the patient take additional tablets to make up for this [Dosage and Administration (2.1 ) for more information.

[0389] Embryo-fetal toxicity Inform patients that ERLEADA may be harmful to the developing fetus. Recommend using effective contraception during treatment and for 3 months after the most recent dose of ERLEADA. Advise male patients with female partners of reproductive potential to avoid sexual intercourse with pregnant women. Advise male patients to use condoms if necessary [Warnings and Precautions] See (5.5)]

[0390] infertility - ERLEADA may impair fertility, and you are currently undergoing treatment with ERLEADA Advise male patients that they should not donate sperm for 3 months after their most recent dose of [See Use in Specific Populations (8.3)] manufacturer: Janssen Ortho LLC Gurabo,PR00778 Manufacturer Alternative Name Janssen Products,LP Horsham,PA 19044 (Copyright) 2019 Janssen Pharmaceutical Company ies

[0391] [Table 19-1]

[0392] [Table 19-2] This patient information has been approved by the U.S. Food and Drug Administration. Revised: September 2019

[0393] The examples and embodiments described herein are for illustrative purposes only and are not intended to be limiting unless otherwise indicated and should not be construed as limiting the scope of the invention as claimed. Various modifications or variations are within the spirit and scope of this application and the appended claims. .

Claims

1. A method for treating metastatic castration-sensitive prostate cancer in a human male, comprising administering to said patient an effective amount of The present invention relates to administering a dose of an antiandrogen to human males with metastatic castration-sensitive prostate cancer. wherein the antiandrogen comprises 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl -4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzyl Nzuamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6- Thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl thiobenzamide, or N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole -1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole 3-carboxyamide.

2. Administration of the antiandrogen to the human male population having metastatic castration-sensitive prostate cancer and wherein said population provides an increased overall survival of said human males compared to the overall survival of an androgen-positive human male.

2. The method of claim 1, wherein a placebo is administered in combination with the phosphodiesterase ablation therapy.

3. Administration of the antiandrogen to the human male population having metastatic castration-sensitive prostate cancer and providing an increased progression-free survival rate for said human males compared to a progression-free survival rate for said human males of said population, 3. The method according to claim 1 or 2, wherein a placebo is administered in combination with androgen deprivation therapy. 。

4. said male human having undergone at least one prior therapy for the treatment of cancer; The prior therapy for the treatment of the cancer is selected from the group consisting of radiation therapy, surgical intervention, and dosing. The method according to any one of claims 1 to 3, which is taxel therapy.

5. The method of any one of claims 1 to 3, wherein the human male is treatment naive.

6. The antiandrogen is 4-[7-(6-cyano-5-trifluoromethylpyridine -3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5 6. The compound according to claim 1, wherein the compound is a 2-fluoro-N-methylbenzamide. The method described above.

7. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- 7. The method of claim 6, wherein N-methylbenzamide is administered to said male human daily.

8. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- 7. The method of claim 6, wherein N-methylbenzamide is administered orally to the male human.

9. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide was orally administered to the male human on a continuous daily dosing schedule. The method of claim 6 .

10. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide at a dose of about 30 mg per day to about 480 mg per day; 7. The method of claim 6, wherein the method is administered orally to the male human.

11. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide at a dose of about 180 mg per day to about 480 mg per day 7. The method of claim 6, wherein the human male is orally administered.

12. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide (a) about 30 mg per day, (b) about 60 mg per day; (c) about 90 mg per day; (d) about 120 mg per day, or (d) orally administered to said male human at a dose of about 240 mg per day. The method described.

13. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide is orally administered to the male human at a dose of about 240 mg per day. The method of claim 6 .

14. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- If said dose of N-methylbenzamide caused grade 3 or greater toxicity in said human male, In the case of claim 13, the dose is reduced to 180 mg per day or 120 mg per day. method.

15. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- 7. The method of claim 6, wherein the N-methylbenzamide is administered in combination with androgen deprivation therapy. The method according to

16. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide is an inhibitor of at least one gonadotropin releasing hormone (GnRH) The method of claim 15 , administered in combination with an agonist or antagonist.

17. The at least one GnRH agonist or antagonist may be leuprolide, buceloside, Relin, naferelin, histrelin, goserelin, deslorelin, degarelix, oza Relix, ABT-620 (elagolix), TAK-385 (relugolix), EP- 100, KLH-2109, or triptorelin, or 16. The method according to claim 16.

18. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- 16. The method of claim 15, wherein N-methylbenzamide is used in combination with bilateral orchiectomy. How to.

19. The 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo xo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro lo-N-methylbenzamide, (a) a drug that is a strong inhibitor of CYP2C8 or CYP3A4, (b) is primarily metabolized by CYP3A4, CYP2C19, or CYP2C9 Drugs, (c) an agent that is a substrate for UDP-glucuronosyltransferase; or (d) P-glycoprotein, breast cancer resistance protein, or organic anion transporting polypeptide. The method of claim 6, which is not administered in combination with an agent that is a substrate of 1B1.

20. The antiandrogen is 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)- Nyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2 2. The method of claim 1, wherein the compound is -fluoro-N-methylbenzamide.

21. The 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl 4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methyl Rubenzamide is orally administered to the male human at a dosage of about 160 mg per day.

21. The method of claim 20.

22. The antiandrogen is 4-[7-[4-cyano-3-(trifluoromethyl)phenyl] nyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl ]-2-fluoro-N-methylbenzamide.

23. The antiandrogen is N-{(2S)-1-[3-(3-chloro-4-cyanophenyl 1H-pyrazol-1yl]propan-2-yl}-5-(1-hydroxyethyl) 2. The method of claim 1, wherein the compound is a 1H-pyrazole-3-carboxyamide.

24. A method for treating metastatic castration-sensitive prostate cancer in a human male, comprising administering to said patient an effective amount of The study was carried out by administering a dose of an antiandrogen to human men with metastatic castration-sensitive prostate cancer. wherein the antiandrogen consists essentially of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl -4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzyl Nzuamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6- Thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methyl thiobenzamide, or N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazole -1yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole- 3-carboxamide.

25. The antiandrogen is 4-[7-(6-cyano-5-trifluoromethylpyridine -3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]octa-5 24. The method of claim 23, wherein the compound is [-yl]-2-fluoro-N-methylbenzamide.

26. 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo -6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro- N-methylbenzamide (a) about 30 mg per day, (b) about 60 mg per day; (c) about 90 mg per day; (d) about 120 mg per day, or (d) orally administered to said male human at a dosage of about 240 mg per day. The method described above.

27. 1. A method of treating metastatic castration-sensitive prostate cancer in a human male, comprising: (a) determining whether the human male has metastatic castration sensitive prostate cancer; and (b) administering an antiandrogen to a patient having a prostate cancer that is therapeutically effective for treating said metastatic castration-sensitive prostate cancer. and administering to a male human an amount of 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo So-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro N-methylbenzamide, 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl (4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methyl benzamide, 4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6 -Thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N- methylbenzamide, or N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazo {5-(1-hydroxyethyl)-1H-pyrazole}-5-(1-yl)propan-2-yl 3-carboxyamide.

28. A method for treating metastatic castration-sensitive prostate cancer using an approved drug product containing apalutamide. The agent is administered to a human male having metastatic castration-sensitive prostate cancer at a dose of 100 mg / kg or more per day as described in the drug product package insert of the formulation. The method comprises administering in an amount.

29. The approved product containing apalutamide is an ANDA product, a label extension product, or a 5 30. The method of claim 28, wherein the compound is a 0.05(b)(2) formulation.

30. The method according to claim 27 to claim 29, wherein the method has been clinically proven to be safe and / or effective.

30. The method of any one of claims 29 to 30.

31. Amounts that have been clinically proven to be safe and clinically proven to be effective A pharmaceutical product comprising apalutamide of formula (I), wherein the pharmaceutical product is packaged and The package is (a) identifying apalutamide as a chemical entity approved by a regulatory agency; (b) providing a package insert directing the use of apalutamide in the treatment of castration-sensitive prostate cancer; Including, pharmaceutical products.

32. 1. A method of marketing an approved drug product comprising apalutamide, said method comprising the steps of: The drug product package insert for such drug product, including the sale of the drug product, is subject to the following restrictions: The method includes instructions for treating tumor-sensitive prostate cancer.

33. 1. A method of making an offer for sale of an approved drug product comprising apalutamide, said method comprising: Reference listings for such preparations, including making offers to sell such preparations; wherein the pharmaceutical package insert includes instructions for treating castration-sensitive prostate cancer.

34. The formulation is an ANDA formulation, a label supplement application formulation, or a 505(b)(2) formulation; 34. The method of claim 32 or 33.

Citation Information

Patent Citations

  • ANDROGEN RECEPTOR MODULATOR AND USES THEREOF

    JP2016508991A